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CHAPTER 1 
GENERAL INTRODUCTION 
1.0 Introduction 
1.1 Autocrine growth stimulation, a concept 
1.2 The epidermal growth tactor receptor and Its role In breast 
carcinogenesis 
1.3 Scope of the thesis 
1.4 References 
f.O Introduction 
Human breast cancer is considered to be a systemic disease even before the 
primary tumor becomes clinically apparent This consideration, combined with the 
knowledge that patients with a limited tumor burden do benefit most from anti-
tumor therapy at advanced disease, led to the introduction of systemic adjuvant 
treatment of clinically non-apparent metastasis in the past decade. At this point in 
time it is dear that subpopulations of patients with breast cancer do benefit from 
systemic adjuvant therapy in terms of a longer disease free and overall survival 
(1.2). 
The patients most often selected for adjuvant therapy are those with disease 
extension to the axillary lymph nodes at first presentation. In this subgroup the risk 
of disease recurrence is the highest, 75% within 10 years. Nevertheless, a 
significant number of the patients without axillary lymph node involvement -50% of 
the patients presenting with primary breast cancer- also develop distant metastasis 
(25%, within 10 years). In order to optimize the yield of systemic adjuvant therapy, 
additional 'measurable' factors capable of identifying those patients at risk of 
disease recurrence, within the subgroups of node negative as well as node positive 
patients, are needed. 
If the patient at risk of disease recurrence can be identified the question arises 
whether she should be treated with multidrug chemotherapy or by endocrine 
measures. 
A factor indicative of response to chemotherapy is not yet available. For endocrine 
treatment the Estrogen Receptor (ER) status of the primary breast tumor is a 
powerful predictor of response at advanced disease (3). Patients with ER-negative 
tumors respond to systemic endocrine treatment in only 10% of the cases, while 
50% of the patients with ER-positive primary tumors have an objective response. In 
addition recent data indicate that also in the case of adjuvant therapy with 
endocrine measures ER is a strong predictor of patients' outcome (1,2). 
The fact that 50% of the patients with ER-positive primary tumors do not respond 
to endocrine treatment at advanced disease has been attributed to loss of ER 
expression during tumor dedifferentiation as well as to the presence of non-
functional ER in these tumors. This 'hypothesis' has stimulated the search for ER 
associated proteins which might potentially serve as more precise predictors of 
hormone sensitivity. 
The receptor for progesterone (Progesterone Receptor, PgR) is such a protein and 
indeed it has been shown that patients with tumors positive for both the steroid 
hormone receptors more often respond to endocrine therapy for advanced disease 
than patients with tumors positive for ER, but lacking the PgR (4). 
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Although very useful, knowledge of the axillary lymph node status and the tumors' 
steroid hormone receptor status do not always provide sufficient information to 
accurately predict the risk of developing distant metastasis and subsequent 
response to systemic treatment for any individual patient. For this reason and for a 
better understanding of breast tumor biology the search for additional factors 
indicative of prognosis and/or response to treatment is indispensable. 
1.1 Autocrine growth stimulation, a concept 
In 1962 Cohen reported the isolation from the mouse submaxillary gland of a 
protein accelerating incisor eruption and eyelid opening in the newborn animal by 
stimulating the proliferation of epidermal basal cells (5,6). Therefore the protein was 
named the Epidermal Growth Factor (EGF). Human EGF is a polypeptide which 
consists of 53 amino acid residues and three disulfide bonds which preserve the 
globular structure of the molecule (7). In man EGF was first isolated from urine 
(8,9). It was called urogastrone as it was shown to inhibit gastric acid secretion (9). 
Moreover, in the late seventies EGF has been used in gastric-ulcer therapy. Its use 
was abolished as it became clear that EGF might also have mitogenic potential. 
The biological effects of EGF are mediated through a specific cell membrane-
bound receptor (10). The receptor, a 170 kDa transmembrane protein (11), 
comprises an extracellular ligand-binding domain which is, by a short hydrofobic 
transmembrane stretch, linked to a cytoplasmic domain expressing an intrinsic 
tyrosine kinase activity (12,13). The latter Is believed to be responsible for post-
receptor signaling. Interest in the role the EGF - EGFR pathway could play in 
oncogenic cell transformation was first raised as the cytoplasmic domain of the 
receptor was shown to have a striking homology with the V-erbB-2 oncogene 
protein (14). The latter is the transforming protein of the avian erythroblastosis 
virus. Moreover, the isolation from the culture medium of 3T3 mouse fibroblasts 
transformed by the Maloney murine sarcoma virus of an activity competing with 
EGF for binding to the EGFR further stimulated researchers to investigate the role 
of the EGF - EGFR system in carcinogenic cell transformation (15). The activity 
was named Transforming Growth Factor α (TGFa) for its ability to confer a 
transformed phenotype upon normal rat fibroblasts and because of the fact that it 
is secreted by transformed cells (15,16). 
The latter finding: a cell producing a transforming activity for which it also 
expresses receptors which can specifically bind and respond to the transforming 
activity led to the concept of autocrine stimulation of tumor growth (17). 
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1.2 The epidermal growth factor receptor and fts role In breast carcinogenesis 
Soon, it was found that EGFR is expressed on breast carcinomas (18). Also, 
EGFfTGFa has been reported to be produced by breast tumors (19,20). In addition 
it was found that in estradiol receptor positive cell lines the production of EGF like 
activity could be induced by estrogen (21,22). The mechanisms by which 
estrogens control the proliferation of human breast cancer remains to be 
completely understood. Apart from a direct stimulation of breast cancer cell growth 
it is possible that estrogen exerts its mitogenic action on breast cells indirectly by 
regulating the synthesis and secretion of growth factors, which, in turn, stimulate 
cell growth. Moreover, abnormal or over expression of these secondary factors 
might be a way by which breast tumor cells overcome their dependence on 
estrogen. 
tt has been shown that transfection with either the activated C-erbB-2 (23) 
oncogene or TGFa gene (24), which leads to overexpression, induced breast 
neoplasms in a mouse mammary tumor model. In contrast, sialoadenectomy which 
decreased salivary EGF levels, dramatically decreases mammary tumor 
development in mice (25). 
Later on additional peptides like Vaccinia Growth Factor (26), amphiregulin (27) 
and crypto (28) have been shown to share sequence homology with EGF and to 
bind to the EGFR. 
Notwithstanding the ever increasing amount of experimental data, to date it is far 
from dear whether and if so, how, EGFR is involved in the process of breast tissue 
carcinogenesis. Unlike in tumor tissue little or no attention has been paid to EGFR 
analysis in normal breast tissue. Normal breast derived cell lines have been shown 
to contain both TGFa-mRNA and EGFR-mRNA, thus to exhibit the complete EGF -
EGFR pathway (29). Also, in an occasional report it is mentioned that in 
'apparently' normal tissue obtained from cancerous breasts EGFR is present 
(30,31). Thus, there are indications that the EGF - EGFR pathway is involved in 
normal breast tissue growth and differentiation. 
The nature of the EGFR ligand(s) involved in breast carcinogenesis has not yet 
been established. EGF-mRNA has been detected in 83% (32), TGFa-mRNA in 42% 
(33) and EGF-like 'activity' in up to 100% (34) of breast cancers. Moreover, it is not 
known how the presence of EGFR ligand(s) relates to the presence of EGFR or to 
prognosis of patients with breast cancer. 
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f.3 Scope of the №es/s 
The studies described in the following chapters were performed, first, to provide an 
overview of the available data on EGFR in human breast cancer Secondly, since 
this thesis represents the clinical part of a combined dinical and analytical study on 
EGFR in human breast cancer, to establish the practical possibilities and limitations 
of an EGFR assay, standardized and quality controlled by the Receptor Study 
Group of the EORTC (European Organization for Research and Treatment of 
Cancer) in human breast tumor derived cell membranes. The development and 
methodology of this assay is extensively described in the doctoral thesis by С Β M 
Kienhuis 'Measurement of the Epidermal Growth Factor Receptor', Nijmegen, 
1992 Thirdly, to study the associations between EGFR as well as between EGFR 
ligand(s) and patients', tumor characteristics Fourthly, to assess the prognostic 
significance of EGFR and EGFR ligand(s) in human breast cancer 
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2.0 Introduction 
In 1984 Fitzpatrick et al.[λ) were the first to assay EGFR in human breast tumor 
biopsy samples. In 1987 Sainsbury et al. (2) reported the presence of this receptor 
to be an indicator of a poor prognosis in human breast cancer. Ever since various 
research groups assayed EGFR in human breast tumor biopsy samples, all of 
them employing different techniques to prepare breast tumor membrane fractions 
as well as techniques to assay EGFR (Kienhuis C.B.M.:'Measurement of the 
Epidermal Growth Factor Receptor, doctoral thesis, University of Nijmegen, 1992). 
Probably as a result of this variability inconsistent associations between EGFR and 
patients' age, menopausal status, tumor size, axillary lymph node status, 
histopathological tumor type and differentiation grade, Estrogen Receptor (ER) and 
Progesterone Receptor (PgR) status, were reported. In addition, at present, 
conflicting reports on the value of EGFR as a prognosis factor in human breast 
cancer are appearing in the literature. 
Before presenting the results obtained while assaying EGFR in a series of 725 
primary human breast tumor biopsy samples an overview of the current EGFR 
literature is presented in this chapter. 
2.1 Review method 
The articles included in this review were obtained from the computerized Medline 
data-base. All papers reporting data on one or more aspects of EGFR and human 
breast tumor biopsy samples, particularly human breast cancer, were included in 
this study. Several groups published more than one paper on the subject; for this 
review the most recent publication was used. 
2.2 EGFR, / е/s and percentages of positive cases 
Radio-ligand binding is the method most often used to assay EGFR in human 
breast tumor biopsy samples. Currently, data on EGFR in 4450 breast tumors, 
assessed by radio-ligand binding assay, are available (Table 2.1). The percentages 
of positives vary from 15 to 93%, with a mean of 40%. Apart from differences in 
tumor membrane preparation and differences in radio-ligand binding assays, also 
the use of different cut-off levels for EGFR-positivity (ranging from 0 to 30 fmol/mg 
of membrane protein. Table 2.1) will also have attributed to this variability. 
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Table 2.1: EGFR, levels and percentages of positives obtained by llgand 
binding assay. 
Author1 N2 Median3 Range3 Cut- %pos4 
off 
Fitzpatrick ef al. 1984(1) 
Perez et al. 1984(3) 
Peyratefa/. 1984(4) 
Sainsbury ef al. 1985(5) 
Skoogefa/. 1986(6) 
Maciasefa/. 1987(7) 
Sainsbury ef a/. 1987(2) 
Wyssefa/. 1987(8) 
Battaglia ef al. 1988(9) 
Capelletti ef a/. 1988(10) 
Delarueefa/. 1988(11) 
Home et al. 1988(12) 
Nicholson ef al. 1988(13) 
Pekonenefa/. 1988(14) 
Ríos et al. 1988(15) 
Sainsbury ef al. 1988(16) 
Barker ef a/. 1989(17) 
Bauknecht ef al. 1989(18) 
Costa et al. 1989(19) 
Feketeefa/. 1989(20) 
Foekensefa/. 1989(21) 
Gnmauxefa/. 1989(22) 
Harris ef al. 1989(23) 
Uorenseffl/. 1989(24) 
Zeilmger ef al. 1989(25) 
Bolla ef al. 1990(26) 
Boluferefa/. 1990(27) 
Fórmenlo ef al. 1990(28) 
Nicholson et al. 1990(29) 
Spyratos ef al. 1990(30) 
Toi ef al. 1990(31) 
Palette ef al. 1992(32) 
137 
95 
65 
108 
37 
72 
135 
238 
89 
136 
100 
50 
246 
171 
225 
264 
44 
59 
68 
335 
214 
68 
228 
67 
50 
177 
220 
105 
231 
109 
91 
216 
r 
11 
e 
A 
27 
4C 
(74! 
10 
(4η 
О) 
I 1-121 
1-64 
4-47 
0-806 
0-120β 
1-137 
l· 5-26 
0-275 
Ι 0-200 
0-34 
3-57 
0-317 
0-33 
10-187 
3-50 
1-102 
0-1448 
1-35 
1 
1 
S.B.5>1% 
10 
10e 
10e 
10 
1 
2 
30 
0 
10 
10 
S.B.>2% 
1 
10 
3 
1 
10 
1 
0 
5 
10 
3 
10 
5 
0.5 
0 
10 
10 
1 
Non-occupied 
Total EGFR 
48 
42 
48 
42 
27 
27 
35 
54 
57 
46 
22 
38 
32 
15 
43 
33 
34 
33 
16 
67 
93 
37 
35 
36 
16 
25 
42 
79 
35 
34 
43 
54 
90 
Name of the first author and year of publicaron 
2
 N = Number of patients on study 
3
 Median (values between brackets are mean EGFR values), range and cut-off, EGFR values 
expressed in fmol/mg of membrane protein 
4
 %pos = percentage of N positive for EGFR 
5
 S.B is specific binding. 
6
 апгаі/ид DNA. 
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The median EGFR levels reported ranged from 1 to 40 fmol/mg of membrane 
protein, the EGFR levels of individual tumors ranging from 1-1448 fmol/mg of 
membrane protein. One group assessed EGFR In both a direct assay (the one 
commonly used) and an indirect EGFR assay, the latter after acid-treatment of the 
EGFR containing cell membranes (32). In this way EGFR sites occupied by 
endogenous ligand(s) become accessible to the (exogenously added) EGFR 
tracer. The percentage of EGFR-posrtive breast tumor biopsy samples was found 
to increase from 54% to 90% due to pre-treatment of the tumor membranes, which 
led the researchers to conclude that the EGFR is occupied by endogenous ligand 
in 36% of the cases. In our laboratory C.B.M. Kienhuis was not able to reproduce 
their results, moreover, as described In his doctoral thesis: 'Measurement of the 
Epidermal Growth Factor Receptor', Nijmegen, 1992, he showed that acid 
treatment did not disclose additional EGFR. 
A histochemical variation of the ligand binding assay, autoradiography, has been 
used by two research groups (33,34). One group found EGFR In 64% (32 out of 
50) of breast tumor biopsy samples (33), the other in 28% (11 out of 36) (34). 
The third method used to assay EGFR in human breast tumor biopsy samples is 
immunohistochemistry. A total of twelve research groups assessed EGFR while 
using the monoclonal antibody EGFR1 (52). In this way 951 primary breast tumor 
biopsy samples were analyzed (Table 2.2). The percentages of EGFR-positive 
tumors reported ranged from 14% to 65%, with a mean of 40% (Table 2.2). 
One group used the EGFR1 antibody to design a quantitative assay, the so-called 
IEMA (immunoenzymetric assay) (46). TTiey found EGFR to be present in 69 (31%) 
out of 220 invasive ductal carcinomas, introducing a cut-off level for EGFR-positivity 
of 20 fmol/mg of membrane protein. 
In addition to EGFR protein expression two groups assessed EGFR-mRNA 
expression in a total of 328 cases and found EGFR-mRNA to be present in 49% of 
the cases (47,48). 
2.3 EGFR, assoclaUons with patient and tumor characteristics 
The association between patient age and EGFR was studied by 11 groups (Table 
2.3). Nine of them found no significant association between patient age and EGFR, 
whereas two groups found a negative association between patient age and EGFR. 
The association between EGFR and the patients' menopausal status was assessed 
by eight groups (Table 2.3). Seven of them found no association between the 
patients' menopausal status and EGFR, one found a negative association. 
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Table 2.2: EGFR, percentages of positives obtained by Immunohlstochemistry 
using the EGFR1 antibody. 
Author1 N2 %pos3 
Walker ef al. 1986(35) 
Hörne et el. 1988(12) 
Wrbaefa/. 1988(36) 
Betta et al. 1989(37) 
Moller étal. 1989(38) 
Toi eí al. 1989(39) 
Bevilacqua ef al. 1990(40) 
Lewis ef al. 1990(41) 
Kommossefa/. 1990(42) 
Tsutsumi ef al. 1990(43) 
Hamsworth ef al. 1991(44) 
Мое et al. 1991(45) 
Name of the first author and year of publication. 
2
 N = Number of patients on study 
3
 %pos » percentage of N positive for EGFR 
48 
57 
88 
54 
197 
50 
134 
87 
55 
36 
71 
74 
42 
28 
60 
65 
20 
34 
51 
14 
60 
50 
17 
25 
The association between EGFR and pT, pN, tumor histology or the tumors' 
histological differentiation grade has been investigated by 20, 20, 7 and 22 groups, 
respectively (Table 2.3). 
For pT and EGFR, 13 out of 20 groups found no association, four groups found a 
positive association and three groups found a significant negative trend between 
EGFR and tumor size. As far as the association between EGFR and pN was 
concerned only two out of 20 groups found a significant (positive) association 
between EGFR and pN. Seven groups assessed the association between EGFR 
and tumor histology. 
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Three groups found EGFR protein expression to be lower in lobular carcinomas, if 
compared with invasive ductal carcinomas (Not Otherwise Specified, NOS), four 
groups found no association between EGFR and tumor histology. With respect to 
the association between EGFR and the tumors' histological differentiation grade, 14 
out of 22 groups found a positive association (Table 2.3). 
The association between ER and EGFR has been assessed in 33 out of the 36 
reports listed in Table 2.3. Despite differences in ER assays, 29 out of the 33 
groups found a significant negative association between ER and EGFR. The 
association between PgR and EGFR has been assessed by 20 groups. Thirteen of 
them found a negative association between PgR and EGFR (Table 2.3). 
2.4 EGFR, a prognostic factor In human breast cancer? 
In 1987 Sainsbury ef al. (2) reported EGFR to be an independent factor affecting 
prognosis of patients with primary breast cancer, with respect to Disease Free 
Survival (DFS) as well as with respect to Overall Survival (OS) (Table 2.4). Later on 
in 1989 Nicholson et al. (53) showed that EGFR also predicted response to 
endocrine treatment for advanced disease, patients with (ER+) EGFR+ primary 
tumors being hormone resistant. Ever since, nine additional groups investigated the 
prognostic value of EGFR protein expression in human breast cancer. Five of them 
found EGFR to be significantly associated with DFS, the four others did not. In 
addition two groups investigated the association between EGFR and OS, one 
found a very strong, statistically significant association, the other did not. 
In one study the association between EGFR-mRNA expression and DFS as well as 
OS was analyzed but no significant associations were found (48). 
2.5 Discussion 
A vast body of data concerning the presence of epidermal growth factor receptors 
in primary human breast cancer has emerged in the literature. As can be read from 
Table 2.1 the percentages of EGFR positivity obtained by ligand binding assay vary 
from 15 to 93%. The immunohistochemical data (Table 2.2), obtained with the 
EGFR1 antibody, show similarly, variable results, percentages of EGFR-positivity 
varying from 17 to 60%. Despite the enormous variation in the percentages of 
EGFR positives by either method, the mean percentage of EGFR positive breast 
tumor biopsy samples (± 40%) is, probably by chance, similar for both methods. 
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Table 2.3: EGFR, associations with patient and tumor characteristics. 
Author1 age3 meno4 pT pN His5 Diff* ER PgR 
Fitzpatrick ef al. 1984(1) 
Perez et al. 1984(3) 
Peyratefa/. 1984(4) 
Sainsbury et al. 1985(5) 
Skoogefa/. 1986(6) 
Walker ef al. 1986(35) 
Maclas eia/. 1987(7) 
Sainsbury et al. 1987(2) 
Wyssefa/. 1987(8) 
Battaglia ef al. 1988(9) 
Capelletti ef al. 1988(10) 
Delaruee/a/. 1988(11) 
Horneefa/. 1988(12) 
Pekonenefa/. 1988(14) 
Riosefa/. 1988(15) 
Wrbaefa/. 1988(36) 
Spitzer ef al. 1988(33) 
Barker ef al. 1989(17) 
Betta ef al. 1989(37) 
Costa ef al. 1989(19) 
Feketeefa/. 1989(20) 
Foekensefa/. 1989(21) 
Grimauxef al. 1989(22) 
Harris et al. 1989(23) 
Uorensefa/. 1989(24) 
Möller et al. 1989(38) 
Bevilacqua ef al. 1990(40) 
Bolla et al. 1990(26) 
Boluferetal. 1990(27) 
Fórmenlo ef al. 1990(28) 
Grimauxef al. 1990(46) 
Lewis ef al. 1990(41) 
Spyratos ef al. 1990(30) 
Toiefa/. 1990(31) 
Hainsworth ef al. 1991 (44) 
Palette ef a/. 1992(32) 
137 
95 
65 
108 
37 
48 
72 
135 
238 
89 
136 
100 
57 
171 
225 
88 
50 
44 
54 
68 
335 
214 
68 
228 
67 
197 
134 
177 
220 
120 
220 
87 
109 
91 
71 
216 
ne 
ne 
neg 
ne 
neg 
ne 
ne 
. 
ne 
ne 
ne 
ne 
. 
ne 
neg 
ne 
ne 
ne 
ne 
ne 
ne 
. 
pos 
. 
ne 
pos 
. 
neg 
ne 
ne 
ne 
pos 
ne 
ne 
neg 
ne 
pos 
ne 
neg 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
pos 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
pos 
с 
с 
ne 
ne 
с 
ne 
ne 
ne 
pos 
ПС 
pos 
pos 
pos 
pos 
ne 
pos 
ne 
ne 
pos 
pos 
pos 
nc 
pos 
pos 
pos 
nc 
nc 
pos 
pos 
nc 
neg 
nc 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
nc 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
nc 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
nc 
nc 
neg 
neg 
neg 
neg 
neg 
nc 
neg 
neg 
nc 
neg 
nc 
neg 
nc 
neg 
nc 
neg 
neg 
neg 
Name of the first author and year of publication. 2 N = Number of patients on study. 3 Patient 
age. 4 Patient menopausal status. 5 Tumor histology. β Tumor histological differentiation grade. 
.= no association assessed, neg=statistically significant negative association, pos= statistically 
significant positive association, c= statistically significant association, nc= no statistically 
significant association. 
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Table 2.4: EGFR and prognosis of patients with breast cancer. 
Author1 
Maciasefa/. 1987(7) 
Samsbury ef al 1987(2) 
Costa ef al 1988(49) 
Ríos efe/ 1988(15) 
Gnmauxefa/ 1989*(46) 
Foekenseta/. 1989(21) 
Coombeseia/ 1990#(48) 
Lewis ef al. 1990*(41) 
Spyratosefa/ 1990(30) 
Nicholson et al 1991(50) 
Toi et al. 1991(51) 
Ν
2 
72 
135 
376 
225 
55 
203 
64 
88 
109 
231 
135 
EGFR3 
27 
35 
43 
37 
93 
55 
14 
34 
35 
41 
FU4 
±40 
33 
12 
±15 
66 
42 
42 
±18 
60 
45 
31 
ADJUe 
C/H 
no 
C/H 
C/H 
C/H 
no 
C/H 
Η 
C/H 
DFS OS 
ne 
p<0 001 p < 0 001 
p<0 01 
p<0 05 
ne ne 
ne 
ne ne 
p<0003 
ne 
p<0001 p<0 001 
p<0 05 
1
 Name о» the first author and year of publication. 2 N = Number of patients on study 3 
Percentage of EGFR-positive primary breast tumors * Median follow-up hi months. 5 Type of 
systemic adjuvant treatment, = unknown, no= no patients received adjuvant systemic treatment, 
C= multidrug chemotherapy, H= hormonal treatment 
#EGFRmRNA, *lmmunohistochemistry 
If compared with the former, the IEMA (46) also employing the EGFR1 antibody 
(52), seems to lack sensitivity (30% of EGFR positive tumor biopsy samples) 
Nevertheless it should be kept in mind that the IEMA used a cut-off level for EGFR 
positivrty of 20 fmol/mg of membrane protein, which might have negatively affected 
the percentage of EGFR positives In fact studies dealing with mRNA reported 
EGFR-mRNA to be present in 50% of breast tumor biopsy samples (47,48) 
Lack of a standardized EGFR assay and of a consensus on the membrane fraction 
to be used, probably are the most important causes for the variability in results 
obtained by ligand binding The vanabilrty in EGFR data obtained by 
immunohistochemistry is probably also attributable to differences in staining 
techniques and/or to differences in the final appreciation of the slides 
From the associations between patient and tumor characteristics (Table 2 3) on the 
one hand and EGFR on the other, it is clear that -apart from a weakly negative 
association between EGFR, patients' age and menopausal status, conflicting results 
on the association between EGFR and tumor size, a trend towards lower levels of 
EGFR expression in lobular carcinomas, a positive association between EGFR and 
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histological tumor differentiation grade and an incidental report on a positive 
association between EGFR and the axillary lymph node status- only a negative 
assoaation between EGFR and the tumors' steroid hormone receptor status seems 
well established. Last but not least, also the associations between EGFR and the 
time of disease free and overall survival are at variance (Table 2.4). 
A comparison of literature data as performed in this review is rather precarious. 
Moreover, a comparison of the associations reported by the various groups 
between EGFR data and patient as well as tumor characteristics, is, in view of the 
variability in EGFR data, probably not allowed. 
Facing the variability in EGFR data listed in this chapter, the only firm conclusion 
that can be drawn from this review is that standardization of EGFR assays Is of the 
utmost importance to attain uniformity and comparability of EGFR data, a 
prerequisite when trying to determine the significance of EGFR as a prognostic 
marker in human breast cancer and its role in tumor biology. 
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3.0 Introduction 
Early 1990 the Department of Experimental and Chemical Endocrinology from the 
University Hospital in Nijmegen, The Netherlands, established a multiple point 
ligand binding assay to determine Epidermal Growth Factor Receptor (EGFR) in 
human breast tumor biopsy samples. This assay was later on adopted by the 
Receptor Study Group of the EORTC (European Organization for Research and 
Treatment of Cancer), to emulate as a standard for assaying EGFR in human 
derived tissue biopsy samples. Using EGFR containing human placental 
membranes (HPM) as a binding protein, this assay was converted into a radio 
ligand competition assay by which EGFR ligand(s) could be measured in tumor 
derived cytosols. For an elaborate description of both EGFR and EGFR ligand(s) 
assays the interested reader is referred to the doctoral thesis by C.B.M. Kienhuis: 
'Measurement of the Epidermal Growth Factor Receptor', Nijmegen, 1992. 
In the present chapter a brief summary of the analytical and statistical methods 
used throughout this study is provided. 
3.T Steroid hormone receptor assays 
These were performed within 4 weeks following surgery, utilizing the dextran-
coated charcoal (OCC) method and multiple point technique as recommended by 
the EORTC (1). In short: after pulverization in the frozen state the tumor biopsy 
sample was homogenized by means of a micro dlsmembrator and dissolved in 1 
ml of assay buffer (0.01 M phosphate buffer, pH 7.4, containing 0.01 M 
KgHPOVKHjPO,, 0.0015 M «¡¡EDTA, 0.003 M №N3, 0.01 M monothioglycerol and 
10% v/v glycerol). The homogenate was centrifuged for 15 minutes at 800g, 4<,C, to 
spin down nuclei and other coarse cell fragments. The supernatant was centrifuged 
for 60 minutes at 105,000g, 4<>C and subsequently used for Estrogen Receptor 
(ER) and Progesterone Receptor (PgR) determinations. Cut-off values for ER and 
PgR were set at 10 fmol/mg of cytosol protein. Ttie cell membrane pellets were 
rinsed with one milliliter of EGFR assay buffer (0.02 M phosphate buffer, pH 7.4, 
containing 0.15 M NaCI and 70 мд/ті bacitracin) and stored at -80oC under an 
aliquot of assay buffer. 
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3.2 Epidermal growth factor receptor assay 
In short: the stored cell membrane pellets were resuspended in 1.1 ml of assay 
buffer by means of ultrasound bursts (MSE Soniprep-150, nominal frequency 23 
KHz., amplitude 10 microns) for 10 seconds, on ice. A 100 μΙ aliquot was taken for 
membrane protein determination (coomassie brilliant blue method using Human 
Serum Albumin as a standard) (2). To the remaining 1 ml of cell membrane sample 
100 μΙ of assay buffer containing 1.1% (w/v) Bovine Serum Albumin was added. 
Eight 100 μΙ aliquots of cell membrane preparation were incubated with 125l-mouse-
EGF (12Sl-mEGF) tracer at concentrations ranging from 0.15 to 3.5 nM in a volume 
of 140 μΙ for 16 hours at 20oC. EGF was ¡odinated using the solid state iodination 
reagent Protag-125™. Non-specific binding was assessed in duplicate using 1 nM 
125l-mEGF and a 250-fold excess of unlabeled mEGF. Receptor-bound and free 
ligand were separated using Hydroxylapatite (HAP). A 100 μΙ aliquot of HAP 
suspension was added to each assay tube (final incubation volume: 240 μΙ, 1 2 S I -
mEGF concentration: 0.1 to 2 nM). The assay tubes were incubated for another 
hour at 20CC, during which they were shaken 4 times. Subsequently the tubes were 
centrifuged for 2 minutes at 800g, 20oC. The supernatant (containing the unbound 
ligand) was decanted. The HAP pellet was washed 2 times with assay buffer (200C) 
before radioactivity was assessed in a gamma-ray counter. A human placental 
membrane preparation containing a fixed amount of EGFR served as a positive 
control for 125l-mEGF - EGFR binding. Receptor values were calculated by 
Scatchard analysis and expressed as fmol/mg membrane protein (3). EGFR 
analyses resulting in interpretable Scatchard plots were regarded positive. Plots 
were regarded interpretable if the correlation coefficient obtained from the 
Scatchard plot, using a minimum of 6 out of the 8 dose points, was found to be 
higher than 0.83 and non-specific binding accounted for less then 50% of total 
binding. 
3.3 Epidermal growth factor radioreceptor assay 
For the measurement of EGFR ligand(s) a 50 μΙ aliquot of tumor cytosol and 
»15000 cpm of 125l-labeled human EGF (huEGF) were incubated in duplicate with 
100μΙ of a human placental membrane preparation containing »500 fmoles of 
EGFR protein/ml, final incubation volume 170 μΙ, for 16 h at 20 "C. A standard 
curve was constructed while using cold huEGF. Receptor bound and free ligand 
were separated as described above. After washing the HAP pellet was counted for 
radioactivity in a gamma counter. 
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3.4 Statistics 
Nonparametric test statistics were applied, since the receptor data were not 
normally distributed. Parametric tests were performed only after logarithmic 
transformation of data. Associations between variables were assessed by the 
Spearman rank correlation test (the correlation coefficient denoted as Rg and the 
significance level as Pg). Homogeneity between groups was tested 
nonparametrically by means of the Wilcoxon two-sample test or the Kruskall Wallis 
test for multiple groups, level of significance denoted as Pw, P ^ respectively. For 
qualitative relations the X2-test for contingency tables was used (level of 
significance denoted as P^). For multivariate analysis of quantitative receptor data 
a multiple regression analysis was applied (level of significance denoted as Ρ
№
ο). 
The categorical modeling procedure served as a matrix for a multivariate analysis 
of the qualitative receptor data (level of significance denoted as POT). TO test for 
homogeneity between distributions of continuous data the Kolmogorov-Smirnov 
test was used (level of significance denoted as PKOL). 
Univariate analysis of survival data was performed using Kaplan-Meier survival 
distribution estimates, development of local/regional relapse or metastasis (Disease 
Free Survival, DFS) or death due to breast cancer (Overall Survival, OS) serving as 
end-points. The log-rank test was used to test for homogeneity across strata for 
survival data. Potential prognostic factors were analyzed in a multivariate way using 
Cox's partially non-parametric proportional hazards model, relative risk denoted as 
RR. Test results were regarded significant at the Ρ<0.05 level. All calculations were 
performed using SAS (Statistical Analyzing System) statistical software (4). 
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4.0 Introduction 
The present chapter focuses on the estimation of Epidermal Growth Factor 
Receptor (EGFR) while using a ligand binding assay standardized in accordance 
with the recommendations of the Receptor Study Group of the European 
Organization for Research and Treatment of Cancer (EORTC) and on the 
associations between EGFR and steroid hormone receptors in human breast tumor 
biopsy samples. 
Since we used stored tumor membrane preparations and no data concerning the 
stability of EGFR during prolonged storage were available, the influence of the time 
of membrane sample storage on EGFR had to be analyzed. Moreover, since the 
tumor membrane preparations were obtained from two patient cohorts -the earlier 
(341 patients) presenting with primary breast cancer between October 1987 and 
August 1988 and the later (384 patients) presenting between May 1989 and May 
1990- and EGFR assays were performed starting in January 1990, it was essential 
to establish whether the two patient cohorts were comparable as far as their EGFR, 
Estrogen Receptor (ER) and Progesterone Receptor (PgR) status was concerned, 
and therefore could be combined for the purpose of clinical studies. In addition, the 
association between EGFR and the membrane samples' protein content was 
assessed as were the associations between EGFR and the tumors' steroid 
hormone receptor content. 
4.1 Patients 
Stored cell membrane preparations of 341 human primary breast tumor biopsy 
samples obtained between October 1987 and August 1988 and 384 cell membrane 
preparations of tumor biopsy samples obtained between May 1989 and May 1990 
were analyzed for EGFR content from January 1990 onward. All cell membrane 
preparations were obtained during routine processing of tumor biopsy samples for 
steroid hormone receptor assays. The following hospitals provided tumor biopsy 
samples for the purpose of this multicenter study: Juliana Ziekenhuis and Lukas 
Ziekenhuis Apeldoorn, Rijnstate Ziekenhuis Arnhem, Stichting 
Ziekenhuisvoorzieningen Gelderse Vallei Bennekom, Geertruiden Ziekenhuis 
Deventer, Stichting Doetlnchemse Ziekenhuizen, Canisius Wilhelmina Ziekenhuis 
Nijmegen, St. Radboud Ziekenhuis Nijmegen, Ziekenhuis Velp, Streekziekenhuis 
Zevenaar and Het Nieuwe Spittaal Zutphen, The Netherlands. 
For a description of assay methodology and of the statistics applied the reader is 
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referred to Chapter 3 and the doctoral thesis by C.B.M. Kienhuis: 'Measurement of 
the Epidermal Growth Factor Receptor', Nijmegen, 1992. 
Table 4.1: Distribution of steroid hormone and EGF receptors over the earlier 
and later patient series. 
EARLIER LATER 
341 384 
ER 
positive N (%) 
median (range)1 
PgR 
positive N (%) 
median (range)1 
EGFR 
positive N (%) 
median (range)2 
254 
104 
224 
93 
167 
42 
(74) 
(10-1500) 
(66) 
(10-1500) 
(49) 
(6-3633) 
283 
109 
267 
92 
186 
45 
(74) 
(10-1300) 
(70) 
(10-1500) 
(48) 
(3-3400) 
0.81 * 
0.58* 
0.22* 
0.25* 
0.89* 
0.74* 
'steroid hormone receptor values, ER and PgR expressed in Imollmg of cytosol protein. 
2EGFR values expressed in Imollmg of membrane protein. 
'Pw, and *Pm 
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4.2 Resufts 
The two seríes of breast tumor biopsy samples were found not to differ in ER, PgR 
and EGFR status (Table 4.1). Subsequent analysis did not reveal any association 
between the varying length of time during which the cell membrane pellets were 
kept at -80eC and their assessed EGFR content (Нд=-0.02, Ps=0.51). Therefore the 
estimations relative to the earlier and the later series were combined for further 
analysis. 
Univariate analysis showed the EGFR levels to be positively associated with cell 
membrane protein levels (1^=0.15, Ps=0.0001), with declining percentages of 
EGFR-positives at the lower cell membrane protein levels (Р
хг
<0.0001), indicating 
that at these levels EGFR concentrations submerged the lower limit of assay 
sensitivity, resulting in false negatives (Fig. 4.1). When EGFR estimations associated 
with cell membrane protein levels up to 0.2 mg/ml were disregarded, the remaining 
estimations showed no further association between EGFR data and cell membrane 
protein levels (Рд=-0.01, Ps=0.74 and P)(2=0.34). Accordingly, a membrane protein 
level of 0.2 mg/ml was adopted as a threshold. In consequence, 27% (194) of the 
EGFR estimations had to be rejected for the purpose of the present study. 
Analysis of the 531 remaining sets of data revealed that 57% (302) of the tumor cell 
membrane preparations contained specific, saturable, high affinity binding sites for 
EGF, EGFR levels ranging from 3 to 3600 fmol/mg membrane protein, median 
value 40 fmol/mg membrane protein (median Kd=0.5 nM, range 0.04-2.6 nM). 
Again, no association was found between EGFR-positivity nor between EGFR levels 
and the duration of storage at -80oC, ranging from 1 week to 3 years (PX2=0.06 
and Ps=0.92; Fig. 4.2). 
Seventy two percent (380/531) of the tumor biopsy samples were ER-positive and 
65% (344/530) were PgR-positive. EGFR-positivity was found in 46% (173/380) of 
ER-positive and in 85% (129/151) of ER-negative breast tumor biopsy samples 
(PX2< 0.0001) as well as in 49% (168/344) of PgR-positive and in 72% (134/186) of 
PgR-negative breast tumor biopsy samples (PX2<0.0001). Mean EGFR levels in ER-
positive breast tumor biopsy samples were significantly lower than they were in ER-
negative ones, 40 ± 31 (mean ± SD) against 72 ± 55 fmol/mg membrane protein 
(Pw<0.0001). Similarly, mean EGFR levels in PgR-positive breast tumor biopsy 
samples were significantly lower than they were in PgR-negative ones, 41 ± 29 and 
70 ± 56 fmol/mg membrane protein (Pw<0.0001). 
In addition, the percentage of EGFR-positive cell membrane preparations 
decreased with increasing ER levels (Pil2= <0.0001; Fig. 4.3) as did the EGFR 
levels (PIW=0.0001; Fig. 4.3). 
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Flg. 4.1: Association between cell membrane protein (expressed as mg/ml, 
displayed as bar endpoints) and the percentages of EGFR positivity (bars 
representing % of Ν, N displayed in the bars). 
Likewise, EGFR-positivity as well as EGFR levels were shown to be negatively 
associated with PgR levels (P<0.0001 and PKW=0.0001, Fig. 4.4).Univariate analysis 
of the EGFR data stratified according to the tumors' combined steroid hormone 
receptor status showed that the absence or presence of ER was the factor 
associated with EGFR-positivity (PX2<0.0001; Fig. 4.5). 
EGFR levels differed significantly between the ER+/PgR+ and the ER-/PgR-
subgroups (Pw<0.0001) but did not differ between the ER+/PgR+ and ER+/PgR-
and not between the ER-/PgR- and ER-/PgR+ subgroups nor between the 
ER+/PgR- and the ER-/PgR+ subgroups (Fig. 4.5). 
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Fig. 4.2: Assodation between the duration of cell membrane preparation storage 
(days, displayed as bar endpoints) and percentages of EGFR positivity (top) (bars 
representing % of Ν, N displayed in the bars) and mean EGFR concentration of 
positives (bottom) (expressed as fmol/mg membrane protein ± SEM). 
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Multivariate analysis introducing EGFR (status and levels) as the dependent 
variable and ER, PgR as independent variables showed that only ER was 
independently associated with EGFR (Рсд,.: ER<0.0001, PgR=0.46 and Ρ,^ ,,: 
ER<0.0001, PgR=0.72), implying that the association between PgR and EGFR is 
an exponent of the strong association between PgR and ER (Rg =0.63, 
Ps <0.0001). 
4.3 Discussion 
The data presented demonstrate that the two patient cohorts included in this study 
were comparable, at least, as far as their tumors' EGFR, ER and PgR status was 
concerned (Table 4.1). In addition the data indicate that EGFR remains stable for at 
least 3 years in cell membrane preparations stored at -80oC, a finding which 
legitimates the use of archived membrane preparations for the purpose of clinical 
studies on EGFR. 
Measurement of EGFR by means of a ligand binding assay is apt to give a false 
negative outcome in cases where the cell membrane protein level falls below a 
certain threshold (in the case of the multiple point HAP-assay, 0.2 mg/ml). The 
amount of cell membrane protein obtained after processing a breast tumor biopsy 
sample is related to its wet-weight (Rs=0.48, Ps=0.0001). The adoption of a cell 
membrane protein threshold of 0.2 mg/ml implies that tumor biopsy samples less 
than 300 mg wet-weight do not qualify for EGFR determination by the multiple point 
assay technique. 
The percentage of EGFR positivity obtained in the present study (57%) is 
significantly higher then the mean percentage of EGFR positivity hitherto reported 
for ligand binding assay as well as immunohistochemistry, about 40%, but fits well 
with that obtained by studies on EGFR-mRNA, 50% (Chapter 2). If compared to 
ligand binding assays this relatively high percentage may be partly attributable to 
our exclusion of false negatives associated with cell membrane protein levels below 
0.2 mg/ml, as well as to the improved sensitivity of the HAP-assay (C.B.M. 
Kenhuis: 'Measurement of the Epidermal Growth Factor Receptor', doctoral thesis, 
Nijmegen, 1992). As far as immunohistochemistry is concerned it has to be 
concluded that the EGFR1 antibody (1) and/or the immunohistochemical 
techniques applied lack sensitivity. 
The median EGFR level in our study (40 fmol/mg membrane protein) also exceeds 
most of the values reported (Table 2.1). 
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Flg. 4.3: Association between the estrogen receptor levels of human primary breast 
tumor biopsy samples (expressed in fmol/mg cytosol protein, displayed as bar 
endpoints) and percentages of EGFR positivity (top) (bars representing % of Ν, N 
displayed in the bars) and mean EGFR concentration of positives (bottom) 
(expressed as fmol/mg membrane protein ± SEM). 
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Flg. 4.4: Association between the progesterone receptor levels of human primary 
breast tumor biopsy samples (expressed in fmol/mg cytosol protein, displayed as 
bar endpoints) and percentages of EGFR positivity (top) (bars representing % of N, 
N displayed in the bars) and mean EGFR concentration of positives (bottom) 
(expressed as fmol/mg membrane protein ± SEM). 
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Flg. 4.5: Association between the combined steroid hormone receptor status of 
human primary breast cancer and percentages of EGFR posiövity (top) (bars 
representing % of Ν, N displayed in the bars) and mean EGFR concentrations of 
positives (bottom) (expressed as fmol/mg ± SEM). 
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In part this higher median EGFR level has to be explained by the beneficial 
properties of the HAP-assay used for the separation of bound from free ligand, if 
compared to ultracentrifugation and filtration methods (C.B.M. Kienhuis: 
'Measurement of the Epidermal Growth Factor Receptor', Catholic University of 
Nijmegen, The Netherlands, thesis, 1992). Also, the use of a multiple point assay 
technique, permitting the extrapolation of EGFR binding data to the abscissa of the 
Scatchard plot, results in higher, more accurate receptor levels than obtainable by 
the single point technique, might have attributed to these relatively high values. 
In line with literature data, both EGFR positivity and EGFR levels were shown to be 
negatively associated with steroid hormone receptor levels. Nevertheless, although 
all the research groups listed in Table 4.2 reported a significant negative 
association between EGFR and ER, the distribution of EGFR amongst the 
subgroups of ER-positive and ER-negative breast tumors varies widely. In the ER-
positlve subgroup we found that 46% (173/280) of the cell membrane preparations 
were EGFR-positive. In the ER-negative subgroup we found 85% (129/151) of the 
breast tumor biopsy samples to be EGFR-positive. This finding is in good 
agreement with in vitro studies in which ER-negative human breast tumor derived 
cell lines were found to constitutively express EGFR (2,3), but is significantly higher 
than the percentages found in Table 4.2. In addition, multivariate analysis showed 
that the association between PgR and EGFR is not an independent one but is an 
exponent of the strong association between ER and PgR. 
The percentages of EGFR positivity as reported in the literature vary considerably. 
Differences in assay methodology and/or tumor biopsy sample selection offer 
plausible explanations for this variation. However, in the case of tumor biopsy 
sample selection one would expect, given the established negative association 
between ER and EGFR, to find the higher percentages of EGFR positivity in studies 
reporting lower percentages of ER-positives. Since this is not the case (Table 4.2) 
methodological differences are the most likely explanation for the observed 
variation. 
Standardization of EGFR assays (as established by the EORTC) is therefore of the 
utmost importance to attain uniformity and comparability of EGFR data, a 
prerequisite when trying to determine the significance of EGFR as a prognostic 
marker in human breast cancer and its role in tumor biology. 
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Table 4.2: Distribution of Epidermal Growth Factor Receptor data over the subgroups of Estradiol Receptor 
positive and negative breast tumors. The ordering of the table Is dictated by Increasing 
percentages of ER-posKlvKy. 
ER + ER -
N %ER + EGFR + EGFR - EGFR + EGFR - %EGFR + 
Bolufer et al.4 
Battaglia et al.5 
Harris et al." 
Rios et al.7 
Sainsbury et al.' 
Perez et al.9 
Toi et al.10 
Grimaux et al.11 
Cappeletti et al.12 
This report 
Delarue et al.13 
Bolla et al.14 
Foekens et al.15" 
220 
89 
228 
225 
135 
95 
91 
68 
136 
531 
100 
177 
195 
34 
40 
43 
45 
47 
51 
60 
68 
70 
72 
76 
77 
78 
23 (10) 
15 (17) 
1 2 ( 5 ) 
29(13) 
4 ( 3 ) 
16(17) 
13 (14) 
12 (18) 
33(24) 
173 (33) 
10 (10) 
26(15) 
97(50) 
52 (24) 
21 (24) 
86(38) 
72 (32) 
60(44) 
32(34) 
42(46) 
34(50) 
62(64) 
207 (39) 
66(66) 
111 (63) 
55(28) 
69(31) 
36(40) 
68(30) 
67(30) 
43(32) 
24 (25) 
26(29) 
13 (19) 
30(22) 
129 (24) 
12 (12) 
18 (10) 
34 (17) 
76(35) 
17 (19) 
62(27) 
57 (25) 
28 (21) 
23 (24) 
10(11) 
9(13) 
1 1 ( 8 ) 
2 2 ( 4 ) 
12 (12) 
22(12) 
9 ( 5 ) 
41 
41 
35 
43 
35 
42 
43 
37 
46 
57 
22 
25 
67 
(N=mimber of patients on study, ()=% of Ν). 'Cut-off level for EGFR set at 0.5 fmollmg membrane protein. 
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CHAPTER 5 
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5.0 Introduction 
Reports concerning the associations between Epidermal Growth Factor Receptor 
(EGFR) data and patients' as well as tumor characteristics are at variance. 
Moreover, the prognostic value of the EGFR is a matter of debate (Chapter 2). In 
the present chapter the associations between EGFR and patient characteristics 
(age, menopausal status) as well as tumor characteristics (size, histopathological 
subtype, histological differentiation grade, axillary lymph node status) are assessed. 
In addition, a preliminary analysis of the time of Disease Free Survival (DFS) and 
Overall Survival (OS) of the patient series, stratified according to EGFR data, is 
provided. 
5. f Patients 
In a prospective multicenter study 459 patients with breast cancer presenting 
between October 1987 and May 1990 were included. The following hospitals 
participated in this multicenter, patient follow-up study: Juliana Ziekenhuis and 
Lukas Ziekenhuis Apeldoorn, Geertruiden Ziekenhuis Deventer, Canisius Wilhelmina 
Ziekenhuis Nijmegen, St. Radboud Ziekenhuis Nijmegen and Het Nieuwe Spittaal 
Zutphen, The Netherlands. Patients were considered eligible to the study if a fresh 
frozen biopsy sample taken from the primary tumor was available for the analysis 
of Estrogen Receptor (ER), Progesterone Receptor (PgR) and EGFR. 
The following patient and tumor characteristics were recorded; patient age, 
menopausal status at first presentation, postoperative tumor size (pT), axillary 
lymph node status (pN), histopathological tumor type and differentiation grade, 
DFS, OS, and first dominant localization of metastasis. The patients were 
considered to be postmenopausal if the last menstruation occurred more than 1 
year before the primary tumor was diagnosed. In all other cases patients were 
considered premenopausal. The axillary lymph node status was considered to be 
negative if all of at least five lymph nodes were found to be free of tumor, and 
positive if tumor was encountered in any lymph node. The histological 
differentiation grade of the invasive ductal carcinomas (Not Otherwise Specified, 
NOS) was assessed on a routine basis in 3 out of the 5 participating pathology 
laboratories according to the criteria provided by Scarff, Bloom and Richardson (1). 
DFS is defined as the interval between surgery and the onset of local/regional 
relapse or metastasis (2). The hierarchy of metastasis with progressively worse 
prognosis is soft-tissue, then bone, then visceral metastasis (3). OS is defined as 
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Table 5.1: Patient and tumor characteristics 
CHARACTERISTIC 
Patients 
. Testai number 
. Mean age (range, in years) 
Menopausal status 
. premenopausal 
. postmenopausal 
. unknown 
Surgical treatment 
. Modified radical mastectomy 
. Breast saving surgery 
. Tumor biopsy/ectomy 
Tumour size 
. pT, <2cm. 
. pT2 2-5cm. 
. pTj 5-10cm. 
•PT* 
Tumor histology 
. Ductal (NOS) 
. Lobular 
. Medullary 
. Tubular 
. Others 
Axilla,y lymph node status 
. Kr de negative 
. Node positive 
. unknown 
Receptors 
. ER status: 
- positive, median1 (range) 
- negative 
. PgR status: 
- positive, median1 (range) 
- negative 
. EGFR status: 
- positive, median2 (range) 
- negative 
N 
459 
(%) 
136 (30) 
321 
2 
268 
132 
(70) 
(58) 
(29) 
59 (13) 
159 
??? 
29 
49 
346 
41 
22 
12 
38 
212 
200 
47 
336 
123 
304 
154 
260 
199 
(35) 
(48) 
( 6 ) 
(11) 
(75) 
(9) 
(5) 
(3) 
(Θ) 
(51) 
(49) 
(73) 
(27) 
(66) 
(34) 
(5η 
(43) 
61 (31-89) 
140 (10-1500) 
105 (10-1500) 
38(3-300) 
Λ/ · Number of patients. 
1
 Expressed in fmollmg of cyroso/ protein. 
2
 Expressed in fmollmg of membrane protein. 
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the time between surgery and the patients' death due to breast cancer (2). 
For the purpose of a study on the associations between EGFR and DFS/OS only 
those patients with unilateral breast cancer were taken into account. Therefore, 
patients presenting with already advanced disease, with bilateral breast cancer and 
patients who suffered from a secondary (non-breast) cancer or any combination of 
these three (in total 83 patients), were not included in this part of the study. 
Of the remaining 376 patients 151 patients with disease extension to the axillary 
lymph nodes received systemic adjuvant therapy, 52 (14%) were treated with 
polychemotherapy including cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF), 96 (26%) received hormonal treatment with tamoxifen and 10 (3%) patients 
received combined chemo/endocrine therapy, comprising both tamoxifen and 5-
fluorouracil. 
For a description of assay methodology and of the statistics applied the reader is 
referred to Chapter 3 and the doctoral thesis by C.B.M. Kienhuis: 'Measurement of 
the Epidermal Growth Factor Receptor', Nijmegen, 1992. 
5.2 Results 
The mean age of the 459 patients included in this study was 61 years at the time of 
first presentation (range 31-89 years). Seventy percent of the patients were 
postmenopausal. Eighty-three percent of the patients had primary tumors less than 
5 cm. in maximum diameter. Seventy-five percent of the tumors were of the 
invasive ductal (NOS) histopathological subtype, in 50% of the cases the tumors' 
histological grade was assessed. Of these tumors 15% were well differentiated 
(Grade I), 50% were of intermediate differentiation grade (Grade II) and 35% were 
poorly differentiated tumors (Grade III). In 49% (212 out of 412) of the patients 
axillary lymph nodes were involved at primary disease. The percentages of ER-
positive, PgR-positive, EGFR-positive tumors were 73, 66 and 57%, respectively 
(Table 5.1). 
The results of univariate analysis of EGFR data stratified according to patients' age, 
menopausal status, pT, pN, histopathological tumor type and differentiation grade, 
and steroid hormone receptor status are shown in Table 5.2. Percentages of EGFR 
positivity did not differ significantly, stratified according to the patients' menopausal 
status, pT, pN or tumor histology. A trend towards a higher frequency of EGFR-
positives in younger women and poorly differentiated (Grade III) tumors could be 
observed. In addition, stratification of EGFR data according to the tumors' steroid 
hormone receptor status showed EGFR to be significantly associated with ER as 
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Table 5.2: Associations between EGFR and patient age, menopausal 
pT, pN, histopathologlcal tumor type, differentiation grade, 
PgR. 
Age 
. ¿50 years 
. >50 years 
Menopausal status 
. pre-menopausal 
. post-menopausal 
Tumor size 
. pT, <2cm. 
. pT2 2-5cm. 
.pTjS-IOcm. 
•PL 
Nodal status 
. node negative 
. node positive 
Tumor histopathology 
. Ductal (NOS) 
. Lobular 
. Medullary 
. Tubular 
. Others 
Differentiation grade 
. Grade 1 
. Grade 2 
. Grade 3 
Estrogen receptor status 
. positive 
. negative 
Progesterone receptor status 
. positive 
. negative 
N 
117 
342 
136 
321 
159 
222 
29 
49 
212 
200 
346 
41 
22 
12 
38 
35 
114 
79 
336 
123 
304 
154 
status, 
ER and 
EokJermal Growth Factor Receotor 
positive 
π (%) 
75(64) 
157 (54) 
85(63) 
174 (54) 
97 (61) 
119(54) 
16 (55) 
28(58) 
117(55) 
114 (5η 
195(56) 
22(54) 
17(77) 
7(58) 
19(50) 
14 (40) 
64(56) 
51 (65) 
152 (45) 
108(88) 
146(48) 
114(74) 
ρ « 
0.06 
0.10 
0.54 
0.71 
0.41 
0.05 
<0.001 
<0.001 
MEAN* 
± s d 
67 + 61 
5 0 ± 4 3 
6 2 ± 56 
51 ± 44 
51 ± 3 9 
58 ± 5 7 
54 + 48 
58 + 48 
55 ± 52 
58 ± 51 
56 ± 4 9 
42 ± 2 5 
72 ± 69 
36 ± 19 
41 ± 3 5 
43 + 31 
58 ± 49 
6 5 ± 6 0 
40 ± 31 
76 ± 61 
41 ± 30 
73 ± 62 
Pw 
0.02 
0.05 
0.94 
0.59 
0.63 
0.50 
<0.001 
<0.001 
'mean of positives, expressed as fmollmg of membrane protein. 
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well as with PgR EGFR was found in 45% of ER-positive and in 88% of ER-
negative breast tumors (Р
Х2<0 001) and in 48% of PgR-positive and in 74% of PgR-
negative breast tumors (PX2<0 001) 
EGFR levels were shown to be significantly higher in women below 50 years of age 
than in older women, mean EGFR level 67 versus 50 fmol/mg of membrane protein 
(Pw=002), with a trend towards higher EGFR levels in premenopausal women In 
addition, mean EGFR levels in ER-posibve breast tumor biopsy samples were 
significantly lower than they were in ER-negative ones, 40 versus 76 fmol/mg of 
membrane protein (Pw<0 001) Similarly, mean EGFR levels in PgR-positive breast 
tumors were lower than they were in PgR-negative ones, 41 versus 73 fmol/mg 
membrane protein (Pw<0 001) No association between EGFR levels and pT, pN, 
tumor histology and differentiation grade was observed 
Multivariate, categorical as well as regression, analysis introducing EGFR as the 
dependent and, patient age, menopausal status and the tumors" ER and PgR 
status as independent variables showed EGFR positivity as well as EGFR levels to 
be solely associated with the tumors' ER status (PCAT= <0 001, Pœo= 0002) 
The median follow-up of the patients (n=376) was 24 months (range 12-50 
months) During this period 64 patients, 29 of which previously received systemic 
adjuvant therapy, developed local/regional and/or distant metastasis Forty patients 
died, 28 of them from breast cancer 
Of the 64 patients with local/regional relapse or metastasis, 22 had an EGFR-
negative and 42 an EGFR-positive primary tumor 9 (14%) had soft tissue, 20 (31%) 
bone and 35 (55%) visceral localizations as first dominant site of metastasis 
Univariate analysis of the metastatic pattern stratified according to the tumors' 
EGFR status showed soft tissue and bone metastasis to be equally distributed over 
the subgroups of patients with EGFR-negative or positive primary tumors (4 vs 5 
and 9 vs 11 patients, respectively) In the case of visceral metastasis a trend, 
although not statistically significant, towards a higher frequency of visceral 
metastasis in patients with EGFR-positive, if compared to patients with EGFR-
negative tumors, was observed (26 vs 9 respectively) 
Univariate analysis showed DFS to be significantly associated with pN, pT, ER and 
PgR In addition a trend towards a positive association between DFS and patients' 
age was found, while for patients with tumors of the ductal carcinoma (NOS) 
subtype a trend towards a negative association between DFS and differentiation 
grade was found No significant association between DFS and menopausal status, 
tumor histology or EGFR could be observed (Table 5 3) 
Since presently no clinically relevant cut-off level for EGFR positivity is available, 
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Table 5.3: Associations between DFS and patient/tumor characteristics. 
CHARACTERISTIC UNIVARIATE MULTIVARIATE 
P-value P-value RR 
Age <50 years> 
pT <2 cm.> (max. diam.) 
pN+/-
histology (NOS vs. non-NOS) 
differentiation grade (NOS only) 
ER+/-
PgR +/• 
EGFR +/-
EGFR <50> (fmol/mg membr. prot.) 
0.07 
0.38 
<0.001 
< 0.001 
0.33 
0.08 
0.03 
<0.001 
0.26 
0.03 
0.04 
0.005 
0.002 
. 
. 
0.73 
0.04 
0.75 
0.57 
2.33 
2.60 
. 
0.88 
0.50 
0.90 
various cut-off levels for EGFR-positivity were analyzed in addition to the negative 
vs. positive partition. It was found that a level for EGFR-positivity of 50 fmol/mg of 
membrane protein was the optimal cut-off level, achieving a maximal, and 
statistically significant, association between EGFR and DFS (Table 5.3, Fig. 5.1). 
Using the latter cut-off level the percentage of EGFR-positives dropped from 56% 
to 22%. 
Multivariate analysis, introducing DFS as the dependent variable and patients' age, 
pT, pN, ER, PgR and EGFR (more or less then 50 fmol/mg of membrane protein) 
as independent variables showed only patients' age, pT, pN and PgR to be 
independently associated with DFS (Table 5.3). 
Univariate analysis showed OS to be significantly associated with pT, pN, ER and 
PgR. No significant associations were found between OS and patients' age, 
menopausal status, tumor histology and differentiation grade (Table 5.4). 
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Table 5.4: Associations between OS and patient/tumor characteristics. 
CHARACTERISTIC UNIVARIATE MULTIVARIATE 
p-value p-value RR 
Age <50 years > 
Menopausal status (pre/post) 
pT <2 cm.> (max. diam.) 
pN+/-
histology (NOS vs. non-NOS) 
differentiation grade (NOS only) 
ER+/ -
PgR +/-
EGFR +/-
EGFR <50> (fmol/mg membr. prot.) 
0.66 
0.59 
0.007 
0.006 
0.23 
0.29 
<0.001 
<0.001 
0.14 
0.002 
0.85 
0.30 
0.03 
0.20 
0.03 
0.89 
1.10 
1.69 
2.83 
0.50 
0.28 
0.94 
With respect to EGFR no association between EGFR, stratified as negative vs. 
positive, and OS could be observed (P=0.14). Again, if 50 fmol/mg of membrane 
protein was introduced as a cut-off level for EGFR positivity a statistically significant 
association between EGFR data and OS was obtained (P=0.002) (Table 5.4, Fig. 
5.2). 
Multivariate analysis, introducing OS as the dependent variable and patients' age, 
pT, pN, ER, PgR and EGFR (more or less then 50 fmol/mg of membrane protein) 
as independent variables showed only pN and PgR to be independently associated 
with OS (Table 5.4). 
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5.3 Discussion 
In the present chapter the associations between EGFR data and patient 
respectively tumor characteristics, as well as DFS and OS were assessed. EGFR 
was shown to be negatively associated with patient age and the tumors' steroid 
hormone receptor status and positively with the tumors' histological differentiation 
grade. No association between EGFR data and menopausal status, tumor size, 
axillary lymph node status or tumor histology could be observed. Despite the 
enormous variation these findings roughly resemble the overall picture of 
associations between EGFR and patient respectively tumor characteristics 
described in the discussion section of Chapter 2. Nevertheless, the associations 
observed between EGFR data and patients' age, the tumors' steroid hormone 
receptor status (the tumors histological differentiation grade, data not shown) do 
not represent independent associations but have to be explained by the 
associations between ER and those factors as well as EGFR. 
Unlike previous studies we present a prospective multicenter study in which high 
risk patients were treated with systemic adjuvant therapy and tumor EGFR protein 
expression was assessed while using a standardized EGFR assay. As can be 
deduced from the tables 5.3 and 5.4, the study population includes a 
representative series of patients with primary breast cancer as far as the 'classical' 
prognostic factors were concerned (Table 5.3 and 5.4). With respect to EGFR, our 
data show that EGFR is a prognostic factor with respect to predicting time until 
relapse (DFS) as well as overall survival (OS). In this respect this study is well in 
line with that of Sainsbury et al. (4). Likewise, a tendency among EGFR-positive 
tumors to preferably metastasize to visceral sites was also observed. 
Apart from these similarities some discrepancies remain. First, as was already 
mentioned in Chapter 4 (Table 4.2) the distribution of EGFR-positivity over the 
subgroups of ER-positive and negative tumors differs enormously between the two 
studies (Table 5.5). This finding might be attributable to differences in percentages 
of EGFR as well as in ER positives. In both respects Sainsbury ef a/. (4) reported 
the lower percentages of positives. If a cut-off level for EGFR-positivity of 30 
fmol/mg of membrane protein and a cut-off level for ER of 60 fmol/mg of cytosol 
protein were introduced in the present study, the percentages of EGFR and of ER 
positives become comparable to those reported by Sainsbury et al. (4). Moreover, 
the distribution of EGFR-positives over the ER-positive and ER-negative subgroups 
then shows similarity (Table 5.5). The latter suggests that differences in EGFR -as 
well as ER-- assay sensitivity might be responsible for the discrepancies observed, 
as was already suggested in Chapter 4. 
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Table 5.5 The effect of cut-off levels on the distribution of Epidermal Growth Factor Receptor data over 
subgroups of Estradiol Receptor positive and negative breast tumors. 
Sainsbury ef al.* 
N 
135 
%ER + 
47 
ER + 
EGFR + EGFR-
4(3) 60 (44) 
EGFR + 
43(32) 
ER-
EGFR-
28 (21) 
%EGFR + 
35 
cut-off level (This study) 
ER1 EGFR2 
10 +/- 376 73 122(32) 154(41) 89(24) 11(3) 56 
10 50 376 73 34(9) 242(64) 49(13) 51(14) 22 
60 30 376 51 30 ( 8) 161 (43) 105 (28) 80 (21) 36 
(N=number of patients on study, ()=% of N). 
1 Expressed in fmol/mg cytosol protein, 2 in fmollmg membrane protein. 
As far as EGFR is concerned this Is most likely since it was shown by C.B.M. 
Kienhuis, in his doctoral thesis: 'Measurement of the Epidermal Growth Factor 
Receptor', Nijmegen, 1992, that the EGFR assay methodology applied by 
Sainsbury ef al. (4) lacks sensitivity if compared with our Hydroxylapatite assay. 
Nevertheless, whereas the EGFR distributions show a close similarity, EGFR, in the 
present study, no longer was of prognostic significance with respect to DFS as well 
as OS if 30 fmol/mg of membrane protein was introduced as a cut-off level for 
EGFR-positivity. 
A factor which has been proposed to explain this discrepancy was the introduction 
in the eighties of adjuvant (hormonal and multidrug chemo-) therapy. The present 
study nevertheless showed that also in a patient series treated with these adjuvant 
regimens EGFR is of prognostic value. 
Looking closer at Table 2.4 it becomes clear that the time of follow-up rather than 
the introduction of adjuvant therapy affects the outcome of a study. In contrast with 
the observation made by Sainsbury et al.(A), who found that the prognostic 
significance of EGFR increased over time, from the studies listed in Table 2.4 it is 
clear that those studies with short term follow-up (12-40 months, median follow-up) 
in general show EGFR to be significantly associated with DFS whereas in studies 
with a longer follow-up no significant associations were observed in analogy to 
previous studies on the associations between DFS and ER (5). 
Sainsbury ef al. (4) and Lewis ef al. (6) found EGFR to be independently associated 
with DFS. Sainsbury ef al. (4) also found EGFR to be independently associated with 
OS. In contrast, we found that EGFR was no longer of prognostic value as soon as 
ER and/or PgR were introduced in the multivariate model with respect to DFS and 
OS. Differences in the percentages of ER-positives (Sainsbury ef a/. (4) 44%, Lewis 
ef al. (6) 64% and the present study 73%) in the different studies might offer an 
explanation for this discrepancy. 
In addition it is clear that the cut-off level introduced for EGFR-positivity and/or 
EGFR assay sensitivity affects the outcome of a study, in terms of prognostic 
significance. This finding is well illustrated in the present study, in which, indeed, 
without the use of a cut-off level for EGFR-positivity (the negative vs. positive 
partition, 57% of EGFR-positives) no significant associations between EGFR data 
and either DFS or OS could be observed, whereas the introduction of a cut-off 
level for EGFR-positivity of 50 fmol/mg of membrane protein, reduced the 
percentage of EGFR positives to 22% and classified the patient series into a cohort 
with a good prognosis (EGFR <50 fmol/mg of membrane protein) and one with a 
bad prognosis (EGFR >50 fmol/mg of membrane protein). 
In conclusion: EGFR, though not independent, is a factor indicative of prognosis in 
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human breast cancer. In view of the relatively short follow-up period covered by our 
study (median follow-up 24 months] and the observed decrease in the prognostic 
value of EGFR over time (Table 2.4], longer follow-up has to be awaited to see if 
this conclusion stands over time. 
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6.0 Introduction 
Research regarding the prognostic value of the Epidermal Growth Factor (EGF)--
Epidermal Growth Factor Receptor (EGFR) pathway in human breast cancer has 
mainly focussed on measuring EGFR itself. To date EGFR data on more than 5000 
primary breast tumors are available (Chapter 2). Remarkably little is known about 
the role the EGFR ligand(s) play in breast tumor initiation and/or progression. In 
general, the poor prognosis of EGFR-positive primary breast tumors is ascribed to 
a higher susceptibility of these tumors to EGFR ligand(s). Apart from EGF (1): 
Transforming Growth Factor о (TGFa) (2), Vaccinia Growth Factor (VGF) (3), 
amphiregulin (4) and crypto (5) have been shown to be able to bind and activate 
the EGFR. 
EGF-mRNA has been detected in 83% (6), TGFa-mRNA in 42% (7) and EGFR 
ligand(s) in 31% (8) up to 100% (9) of primary breast tumors. Data on the 
expression of VGF, amphiregulin or crypto in human breast cancer are not yet 
available. Also, information regarding the prognostic significance of EGFR ligand(s) 
in human breast cancer is lacking. 
Since it is not clear which of the EGFR ligand(s) is involved in breast tissue 
carcinogenesis and tumor cytosol is a limited resource, it was considered 
worthwhile to assay an overall EGFR ligand(s) level while using a radio-competition 
assay. Thus a pilot study was designed in order to study the associations between 
EGFR ligand(s) and EGFR, steroid hormone receptors, patient and tumor 
characteristics as well as prognosis in human breast cancer. 
&f Patients 
The patient series included in this prospective multicenter study consists of 121 
patients with unilateral breast cancer who presented with primary disease between 
May 1989 and June 1990. The following hospitals participated in this study: Juliana 
Ziekenhuis and Lukas Ziekenhuis Apeldoorn, Geertruiden Ziekenhuis Deventer, 
Canisius Wilhelmina Ziekenhuis Nijmegen, St. Radboud Ziekenhuis Nijmegen and 
Het Nieuwe Spittaal Zutphen, The Netherlands. Patients were considered eligible to 
the study if a fresh frozen biopsy sample, taken from the primary tumor, was 
available for analysis of EGFR ligand(s), EGFR, Estrogen Receptor (ER) and 
Progesterone Receptor (PgR). 
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Table 6.1: Patient and tumor characterístics 
CHARACTERISTIC 
Patients 
. Total number 
. Mean age (range, m years) 
Menopausal status 
. premenopausal 
. postmenopausal 
Surgical Treatment 
. Modified radical mastectomy 
. Breast saving surgery 
. Tumor biopsy/ectomy 
Tumour size 
. pT, <2cm 
. pT2 2-5cm. 
. pTgS-IOcm. 
•PT, 
Tumor Histology 
. Ductal (NOS*) 
. Lobular 
.Others 
Nodal Status 
. Node negative 
. Node positive 
. unknown 
Receptors 
. ER status: 
- positive (median, range)2 
- negative 
. PgR status· 
- positive (median, range)2 
- negative 
. EGFR status-
- positive (median, range)3 
- negative 
Postoperative treatment 
. Radiotherapy only 
. Chemotherapy 
. Endocrine therapy 
. Combined Chemo/Endocrme therapy 
. None 
N1 
121 
31 
90 
72 
37 
12 
36 
62 
13 
10 
89 
16 
16 
59 
50 
12 
90 
31 
82 
39 
66 
55 
59 
9 
41 
2 
10 
(%) 
(26) 
(74) 
(60) 
(31) 
(9) 
(30) 
(51) 
OD (8) 
(74) 
(13) 
(13) 
(54) 
(46) 
(75) 
(25) 
(68) 
(32) 
(55) 
(45) 
(49) 
(8) 
(33) 
(2) 
(6) 
61 (31-89) 
145 (10-1500) 
91 (10-1500) 
35(6 -220) 
1 Number of patients 2 Expressed in fmol/mg of cytosol protein 3 Expressed In fmol/mg of 
membrane protein #Nof otherwise specified 
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The following patient and tumor characteristics were recorded, patients' age and 
menopausal status, postoperative tumor size (pT) and axillary lymph node status 
(pN), time until local/regional and/or distant relapse (DFS) and first dominant 
localization of metastasis. The patients were considered to be postmenopausal if 
the last menstruation occurred more than 1 year before the primary tumor was 
diagnosed. In all other cases patients were considered premenopausal. The axillary 
lymph node status (pN) was only considered to be trustfully evaluated if more than 
five or if less, Involved lymph nodes were encountered in the surgical specimen 
obtained from the axilla. When more than one site was involved at the time of first 
relapse and/or distant metastasis, patients were classified according to the 
dominant site. The hierarchy of metastasis with progressively worse prognosis is 
soft-tissue, then bone, then viscera (10). 
Of the 59 patients with disease extension to the axillary lymph nodes 52 received 
systemic adjuvant therapy, 9 were treated with polychemotherapy including 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF), 41 received hormonal 
treatment with tamoxifen and 2 patients received combined chemo/endocrine 
therapy, including tamoxifen and 5-fluorouracil. 
For a description of assay methodology and of the statistics applied the reader is 
referred to Chapter 3 and the doctoral thesis by C.B.M. Kienhuis: 'Measurement of 
the Epidermal Growth Factor Receptor', Nijmegen, 1992. 
6.2 Resulta 
Of the 121 patients with primary, unilateral breast cancer included in this pilot study 
the mean age was 61 years at the time of first presentation (range 31-89 years). 
Seventy-four percent of the patients were postmenopausal. In 72 patients a 
modified radical mastectomy was performed, 37 were treated by breast saving 
surgery and in 12 patients only a tumor ectomy was performed. Eighty-one percent 
of the patients had primary tumors less than 5 cm. in maximum diameter. Seventy-
four percent of the tumors were of the invasive ductal (NOS) histopathoiogical 
subtype. In 46% (59 out of 109) of the patients axillary lymph nodes were involved 
at primary disease. Of these patients 52 were treated by systemic adjuvant chemo 
and/or endocrine therapy. The percentages of patients with ER. PgR or EGFR-
positive tumors was 75, 68, 55 (ТаЫ 6.1). 
In all the 121 cytosols assayed EGFR ligand(s) was detectable, median level 55.8 
fmol/mg of cytosol protein, range 18-210. A significantly, inverse association 
between EGFR ligand(s) and EGFR levels was observed (Рд=-0.18, Ps<0.05). 
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Table 6.2: Associations between DPS and patient/tumor characteristics. 
CHARACTERISTIC UNIVARIATE MULTIVARIATE 
P-value P-value RR 
Age <50 years > 
Menopausal status (pre/post) 
pT <2 cm.> (max. 
pN+/-
ER+/-
PgR +/-
EGPR +/-
diam.) 
EGFR ligand(s) <60> (fmol/mg cyt. prot] 
0.05 
0.18 
0.002 
0.006 
0.71 
0.27 
0.21 
| 0.02 
0.10 
0.11 
0.04 
0.43 
0.15 
0.75 
0.04 
0.23 
2.20 
3.20 
1.87 
0.42 
0.82 
2.81 
In contrast, the EGFR ligand(s) levels were weakly, though positively associated 
with both ER (Rs=0.16, Ps=0.08) and PgR levels (Rs=0.19, Ps=0.04). No 
associations between EGFR ligand(s) and either patients' age or menopausal 
status, nor with tumor size or axillary lymph node status were found (data not 
shown). 
During follow-up (median 20 months) 22 patients developed local/regional and/or 
distant metastasis. Of these patients 5 (23%) had soft tissue, 6 (27%) bone and 11 
(50%) visceral metastasis as first dominant site of metastasis. Introducing the 
median EGFR ligand(s) level (60 fmol/mg of cytosol protein) as a cut-off for EGFR 
ligand(s) positivity, a high EGFR ligand(s) level was found to be negatively 
associated with DFS (P=0.02, Fig. 6.1). In addition, patient age, tumor size and the 
axillary lymph node status were found to be significantly associated with DFS, 
whereas EGFR was not (Table 6.2). 
Multivariate analysis, including patients' age, pT, pN, ER, PgR, EGFR and EGFR 
ligand(s) showed only pN and EGFR ligand(s) to be independently associated with 
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DFS (P=0 04, for both, Table 6 2) 
Univariate analysis of EGFR ligand(s) data stratified according to the tumors' EGFR 
status (negative vs positive partition) showed a significant association between 
EGFR ligand(s) and DFS in the EGFR-posrtive subgroup (P<0 05) In the EGFR-
negative subgroup, so far no association between EGFR ligand(s) data and DFS 
could be observed (P=018) 
6.3 Discussion 
The data provided show that EGFR ligand(s) was ubiquitously present in human 
breast tumors EGFR ligand(s) levels showed a negative association with EGFR 
levels, while they were positively associated with steroid hormone receptor levels 
As can be observed in Table 6 2 the population studied in this pilot includes a 
representative series of patients with primary breast cancer as far as the 'classical' 
prognostic factors were concerned In addition, although our data do not reveal the 
nature of the peptide(s) involved, high EGFR ligand(s) levels (>60 fmol/mg of 
cytosol protein) were found to be assoaated with a shorter DFS in human breast 
cancer, at least in the EGFR positive subgroup 
The detriment in prognosis of patients with EGFR-posrtive primary breast tumors 
was ascribed to a higher susceptibility to endogenous growth factors The 
observed negative association between EGFR ligand(s) and EGFR does not fit with 
this assumption Moreover, and even harder to explain, both high levels of EGFR 
and high levels of EGFR ligand(s) were associated with poor prognosis in human 
breast cancer 
Although EGFR production has been reported to be enhanced by EGF in vitro 
(11,12), as was receptor internalization and degradation, the negative association 
between EGFR and EGFR ligand(s) suggested that the net result of ligand binding 
was receptor downregulation at the level of the plasma membrane in human breast 
cancer Implying that the highest receptor turnover (read EGFR mediated growth 
promoting signal) might have occurred in apparently EGFR-negative breast tumors 
Whatever the interplay between these factors may be, it is of note that in this pilot 
study, EGFR ligand(s) unlike EGFR, were found to be independently associated 
with prognosis of patients with breast cancer 
No information as to the nature of the ligand(s) involved could be provided 
Nevertheless, the discrepancy between studies on EGF-mRNA and TGFa-mRNA, 
which reported EGF-mRNA to be present in 83% (6) and TGFa-mRNA in only 42% 
(7) of primary breast tumors and our data (all tumors producing EGFR ligand(s)) 
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Flg. 6.1: DFS stratified according to the tumors' EGFR ligand(s) level. 
suggested that combinations of growth factors were present in human breast 
tumors. The positive association between EGFR ligand(s) and the tumors' steroid 
hormone receptor level seem to support the in vitro observation that ЕбРДСРа 
production can be stimulated by estrogens in ER-positive breast cancer cell lines 
(13,14). In addition, since ER is associated with epithelial rather than with stromal 
cells in the case of breast carcinomas, this finding suggests an autocrine mode of 
EGFR ligand(s) production. 
In conclusion: EGFR ligand(s), whatever their nature or mode of production may 
be, unlike EGFR, provided independent prognostic information with respect to DFS 
in human breast cancer. 
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7.0 Introduction 
To date more than 5000 primary breast tumors have been analyzed for their 
Epidermal Growth Factor Receptor (EGFR) content (Chapter 2 and Ref 1) In 
contrast, little is known about EGFR in normal breast tissue Nevertheless, EGFR is 
known not to be exclusively expressed on malignant breast cells, EGFR has also 
been detected in non-malignant breast tissue surrounding invasive breast tumors 
(2,3) In addition, normal breast derived cells have been shown to be responsive to 
Epidermal Growth Factor (EGF) in vitro (4,5) 
Data on EGFR ligand(s) in normal breast tissue are limited to a study concerning 
TGFa-mRNA expression in normal breast tissue derived cell lines Interestingly this 
study showed both TGFa-mRNA and EGFR-mRNA to be present (6) 
In Chapter 5, EGFR and in Chapter 6, EGFR ligand(s) were discussed prognostic 
factors in human breast cancer To investigate whether the EGF-EGFR pathway 
also plays a role in normal breast tissue biology it was thought worthwhile to 
investigate both EGFR and EGFR ligand(s) expression in this tissue The data 
obtained were compared to those obtained in the breast carcinomas 
7.1 Patients 
Normal breast tissue biopsy samples were obtained from 36 healthy women 
undergoing reduction mammaplasty for 'mammary hypertrophy' and/or 
'asymmetry', between October 1989 and December 1991 in either the St Jozef 
Hospital in Deventer or the St Radboud Hospital in Nijmegen, the Netherlands The 
tissues were assayed for EGFR, EGFR ligand(s) and Estrogen Receptor (ER) The 
series of patients with breast cancer included in this chapter have been described 
in Chapter 4 and Chapter 6 
For a description of assay methodology and of the statistics applied the reader is 
referred to Chapter 3 and the doctoral thesis by С В M Kienhuis 'Measurement of 
the Epidermal Growth Factor Receptor', Nijmegen, 1992 
7.2 Results 
Normal breast tissue 
All the 36 women undergoing a reduction mammaplasty were premenopausal, 
mean age 28 years (range 17-57 years) Specific, high affinity, EGF binding sites 
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were detected in 32 of the 36 (89%) normal breast tissue biopsy samples. The 
EGFR levels ranged from 5 to 180 fmol/mg of membrane protein (Fig. 7.1), with a 
median EGFR value of 39 fmol/mg of membrane protein (median Kd = 0.40 nM; 
range 0.12-0.78 nM). No association between patients' age and EGFR levels could 
be observed. 
EGFR ligand(s) was detectable in 34 (94%) of the 36 normal breast tissue biopsy 
samples. The EGFR ligand(s) levels ranged from 3 to 220 fmol/mg of cytosol 
protein, median EGFR ligand(s) level 28 fmol/mg of cytosol protein (Fig. 7.2). 
Both EGFR and EGFR ligand(s) were present in 30 out of 36 (83%) normal breast 
tissue biopsy samples. No associations were found between EGFR and EGFR 
ligand(s) levels nor between these two factors and patients' age. 
All the normal breast tissue biopsy samples were negative for ER. 
EGFR end EGFR ligand(s); a comparison between normal and carcinomatous 
breast tissue 
The frequency of EGFR positivity was significantly higher in the normal breast 
tissue biopsy samples, 89% (32 of 36), than in the breast tumor biopsy samples, 
57% (302 of 531) {PX2<0.001). With the exception of three tumors (0.6%) in which 
EGFR levels up to 3600 fmol/mg of membrane protein were found, the EGFR levels 
found in normal breast tissue biopsy samples, 53 ± 39 fmol/mg (mean ± SD) of 
membrane protein and in EGFR-positive breast tumor biopsy samples, 54 ± 38 
fmol/mg of membrane protein, did not differ significantly (Pw=0.88) (Fig. 7.1). No 
normal vs. breast tumor cut-off point could be established. 
Similar results (i.e. differences in percentages of EGFR-positives and virtually equal 
EGFR levels in normal and carcinomatous breast tissue) were obtained if the EGFR 
data from the normal breast tissue biopsy samples were compared to either those 
obtained in breast tumors from premenopausal patients or those of age matched 
controls (data not shown). 
EGFR ligand(s) was found in virtually all (94%) normal breast tissue biopsy samples 
and in all breast tumor biopsy samples. Moreover, in contrast with EGFR, EGFR 
ligand(s) levels were found to be significantly higher in breast tumors, 57 ± 18 
fmol/mg cytosol protein than in normal breast tissue, 30 ± 22 fmol/mg cytosol 
protein (Pw<0.001). Also the distribution of EGFR ligand(s) levels was found to 
differ between primary breast tumor biopsy samples and normal breast tissue 
(PK0L< 0.001) (Fig. 7.2). A normal vs. tumor cut-off point of 60 fmol/mg of cytosol 
protein could be established. 
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Flg. 7.1: Distribution of EGFR levels (expressed as fmol/mg of membrane protein, 
displayed as bar mid points) in normal breast tissue, N=32 (top) and in EGFR-
positive breast tumors, N=302 (bottom), bars representing % of N. 
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breast tumors, N=121 (bottom), bars representing % of N. 
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7.3 Discussion 
All the breast tissue biopsy samples used in this study were histologically verified 
The question whether normal breast tissue obtained from women undergoing 
reduction mammaplasty is representative for normal breast tissue is still open 
Nevertheless, it was as close to normal as could be obtained 
EGFR was readily detectable in 94% of the normal breast tissues, the EGFR levels 
being comparable to those found in the breast cancers Moreover, the dissociation 
constant, Kd, found in the normal breast tissue (Median Kd 0 4 nM) and in 
caranomatous breast tissue (Median Kd 0 5 nM) were similar, suggesting that we 
are dealing with the same type of receptor in both normal and carcinomatous 
breast tissue EGFR ligand(s) was present in 94% of the normal breast tissues It 
remains to be established whether the ligand(s) in the normal and that/those found 
in carcinomatous breast tissue are the same In 83% of the normal breast tissue 
biopsy samples both EGFR and EGFR ligand(s) were present Indicating, that apart 
from a role in breast tissue carcinogenesis, the EGF - EGFR pathway might be 
implicated in normal breast tissue growth and differentiation Unlike in breast tumor 
tissue no association between EGFR and EGFR ligand(s) could be observed 
Neither an associations between ER and EGFR nor EGFR ligand(s) could be 
assessed since all normal breast tissue biopsy samples were ER-negative, ER was 
assessed by means of ligand binding 
Nevertheless, in an immunohistochemical pilot study performed in close 
collaboration with the department of pathology, University Hospital Nijmegen (head 
D Ruiter), ER was demonstrated to be present in normal breast tissue In this 
immunohistochemical pilot study EGFR was shown to be specifically associated 
with epithelial cell membranes (unpublished observation) 
The fact that EGFR was found in the normal breast tissues is in good concordance 
with the observation that normal breast tissue denved cells are responsive to EGF 
in vitro (4,5,6) and the fact that EGFR-mRNA expression has been found in normal 
breast tissue derived cell lines (3) Since, EGFR was also found in 90% of 
'apparently' normal breast tissues obtained from tumor bearing breasts (2,3) it is 
assumed that the breast tissue obtained from reduction mammaplasty is 
representative for normal breast tissue 
The percentage of EGFR-posrtive normal breast tissue biopsy samples (89%) was 
significantly higher than that of EGFR-posrtive breast tumor biopsy samples (57%) 
With the exception of three breast tumors, EGFR levels were similar in normal and 
in EGFR-posrtive breast tumor biopsy samples Probably only in the three (0 6%) 
breast tumors in which extremely high EGFR levels were found the EGFR gene was 
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amplified (7,8,9) 
The detriment in prognosis of patients with EGFR-positive breast tumors has been 
ascribed to a higher level of tumor EGFR with a concomitant increased 
susceptibility of these tumors to endogenous EGFR ligand(s). In contrast with this 
supposition EGFR levels in normal breast tissue were found to be equal to those in 
EGFR positive breast tumors Moreover, EGFR-positivrty was found more frequently 
in normal breast tissue than in breast tumors. These findings do not suggest high 
tumor levels of EGFR to be an explanation for the observed detriment in prognosis. 
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CHAPTER 8 
GENERAL DISCUSSION 
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Tumor characteristics as there are size (pT), histopathological tumor type, 
histological differentiation grade and axillary lymph node status (pN) as well as 
patients' age are well established prognostic factors in human breast cancer In 
addition, it has now been recognized that the steroid hormone receptor status 
(Estradiol (ER) and Progesterone Receptor (PgR) status) of the primary tumor is a 
prognostic factor, as well as a tod for selecting the appropnate -adjuvant and/or 
palliative- treatment strategy Nevertheless, knowledge of all these factors is still, 
by and large, insufficient to determine the prognosis as well as to select the 
appropriate treatment for an individual patient Since still little is known about the 
exact role the steroid hormones and their receptors play in breast tumor biology it 
was thought worthwhile to further investigate this receptor pathway by studying 
steroid hormone receptor associated factors Literature data indicated the 
Epidermal Growth Factor Receptor (EGFR) to be a prognostic factor in human 
breast cancer As it became clear that EGFR and ER were somehow interrelated, a 
choice was made to study the prognostic value of EGFR and its ligand(s) in a 
prospective study 
In contrast with the nuclear steroid hormone receptors, EGFR is located at the cell 
membrane and internalized after hgand binding and might subsequently be 
downregulated In case of ER and PgR the llgands have been well established 
(estradiol and progesterone, respectively) whereas in the case of EGFR there are 
five possible candidates which can all bind to and activate the receptor At the start 
of this study no standardized EGFR assay was available, a factor which might be 
held responsible for the enormous variability in EGFR data as well as in 
associations reported to exist between EGFR data and patient characteristics, 
tumor characteristics and Disease Free Survival (DFS) as well as Overall Survival 
(OS) in human breast cancer Last but not least, specific, well characterized 
antibodies for most of the EGFR ligands were lacking 
Therefore, first, EGFR assay methodology had to be established and standardized 
In addition, provided the limited resource in tumor cytosol, a decision had to be 
made whether to assay one of the EGFR ligands (human Epidermal Growth Factor 
or human Transforming Growth Factor a) for which antibodies were available, or an 
overall EGFR binding protein level, without discriminating between nor 
characterizing the possible factor(s) involved 
Early 1990 an EGFR assay was established involving Hydroxylapatite (HAP) for the 
separation of bound and free ligand Later on this so called HAP assay was 
adopted by the Receptor Study Group of the EORTC (European Organization for 
Research and Treatment of Cancer) as the standard to assay EGFR in human 
derived tissue biopsy samples Moreover, introducing an EGFR containing human 
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placental membrane (HPM) preparation as a binding protein, this assay was 
converted into a binding competition assay, suitable to assay the level of EGFR 
ligand(s) in human breast tumor cytosols. The methodological minutes of both the 
EGFR (HAP) assay and the binding competition assay are described in the 
doctoral thesis by C.B.M. Kienhuis: 'Measurement of the Epidermal Growth Factor 
Receptor', Nijmegen, 1992. Since it was not dear which of the EGFR ligand(s) is 
(are) involved in breast tissue carcinogenesis this binding competition assay was 
used to measure an overall level of cytosol EGFR ligand(s). 
Like most of the research groups involved in the search for prognostic factors in 
human breast cancer, a start was made by analyzing 725 breast tumor membrane 
preparations for the presence of EGFR using the HAP-assay. Since no data on 
receptor stability during prolonged storage were available and for the present study 
cell membrane preparations, stored for up to 3 years were used, the first issue that 
had to be addressed was that of the stability of EGFR during storage. К was found 
that provided the conditions in the laboratory (storage of isolated cell membranes 
at -800C, under an aliquot of bacitracin containing buffer) EGFR remained stable for 
at least three years. In addition, the association between EGFR and the membrane 
samples' protein content was assessed. An association was found between the 
tumors' cell membrane protein content and the associated percentage of EGFR-
positives. Nevertheless, this association was only apparent at the lower levels of 
membrane protein, indicating that at these lower levels EGFR submerged the 
detection limit of the HAP-assay. Subsequently, a protein threshold of 0.2 mg/ml 
was adopted to avoid the introduction of false negative test results. As a 
consequence 194 out of the 725 EGFR determinations had to be rejected for the 
purpose of the clinical studies. 
In 57% of the remaining 531 cell membrane preparations EGFR was found. A 
percentage that is higher than obtained in most of the previous studies on EGFR 
(40% EGFR-positives, for ligand binding assay as well as immunohistochemistry). 
With the exception of three tumors, EGFR levels ranged from 3-300 fmol/ mg of 
membrane protein. In these three tumors EGFR levels from 1500 up to 3600 
fmol/mg of membrane protein were found. As previously reported EGFR data were 
found to be negatively associated with both the tumors' ER and PgR status. 
Stratification of the EGFR data according to the ER status of the tumor showed 
EGFR to be absent in about 50% of the ER-positive tumors and in 10% of the ER-
negative tumors, a distribution which very closely resembles that of the 
percentages of patients with advanced breast cancer resistent to endocrine 
treatment. TTiis raised hope that EGFR could provide additional prognostic 
information as well as serve as a criterion additional to ER while selecting the most 
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appropriate -adjuvant and/or palliative- treatment strategy, as was already 
suggested in the literature 
The prospective patient follow-up study revealed a negative association between 
EGFR and patient age Also, a trend towards lower EGFR levels in postmenopausal 
women and a higher frequency of EGFR positivity in poorly differentiated tumors 
was observed Nevertheless, the only factor independently associated with EGFR 
positivity and EGFR levels was shown to be the tumors' ER status 
EGFR was shown to be significantly associated with prognosis, in terms of a 
shorter DFS as well as a shorter OS in human breast cancer for patients with a 
tumor EGFR level exceeding 50 fmol/mg of membrane protein Using this EGFR 
level to define EGFR positivity the percentage of EGFR-positwe tumors dropped 
from 56% to 22% In addition, patients' age, pT, differentiation grade, pN, ER and 
PgR were also found to be significantly associated with prognosis Multivariate 
analysis, however, showed that apart from pN, of the receptors only PgR, was 
independently associated with prognosis, but the prognostic value of EGFR was 
shown to be dependent on its association with the steroid hormone receptors (ER 
and PgR) 
In a pilot study the presence of EGFR ligand(s) was found in all the 121 tumor 
cytosols analyzed In addition rt was found that high levels of EGFR ligand(s) (>70 
fmol/mg of cytosol protein) were associated with poor prognosis Moreover, EGFR 
ligand(s) and EGFR levels were found to be negatively associated, whereas EGFR 
ligand(s) and steroid hormone receptor levels showed a positive association 
The negative association observed between EGFR ligand(s) and EGFR levels might 
indicate that the membrane associated expression of EGFR is downregulated by 
endogenous growth factors, but conflicts with the popular belief that the detriment 
in prognosis of patients with EGFR-positive human breast cancers has to be 
ascribed to a higher susceptibility of these tumors to endogenous growth factors 
In turn, these data indicate that the highest EGFR mediated growth promoting 
activity might occur in 'apparently' EGFR-negative breast tumors The fact that 
both, high levels of EGFR and of EGFR ligand(s), two factors showing a negative 
association, were both associated with a poor prognosis in human breast cancer 
remains hard to explain It should however be kept in mind that in contrast to 
EGFR, only EGFR ligand(s) demonstrated an independent association with DFS 
Although our data do not offer any indication as to the nature of the EGFR 
ligand(s) involved, nor to the mode of its producten, the positive association 
observed between steroid hormone receptors, the latter specifically expressed in 
breast epithelial cells, and EGFR ligand(s) suggests an autocrine mode of their 
production 
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No information regarding the value of EGFR data in predicting benefit from 
adjuvant systemic therapy -longer DFS-- or response to palliative treatment for 
advanced disease are yet obtainable from the prospective study. Nevertheless, 
data obtained in a study on ER, PgR, EGFR and EGFR ligand(s) in an in vivo 
mouse mammary tumor model by C.B.M. Kienhuis, as described in his doctoral 
thesis entitled: 'Measurement of the Epidermal Growth Factor Receptor, Nijmegen, 
1992, recently showed that high EGFR levels - and low ER levels- are associated 
with hormone independence in this model. As described in the present study on 
human breast cancer also in this mouse mammary tumor model a negative 
association between ER and EGFR as well as between EGFR ligand(s) and EGFR, 
together with a positive association between ER and EGFR ligand(s) was observed. 
Therefore it is hoped that this mouse mammary tumor model might serve as a 
model to study in more detail the role the EGF-EGFR pathway plays in breast 
tumor carcinogenesis and its interactions with the steroid hormone receptor 
pathway. 
EGFR and EGFR ligand(s) were also assayed in 36 normal breast tissue biopsy 
samples obtained from mammaplasty. In contrast with most expectations EGFR 
was shown to be present in 32 out of 36 (90%) of the normal breast tissue biopsy 
samples, indicating that rather the loss of EGFR than its expression is a factor 
associated with malignancy (only 57% of the tumors are EGFR-positive). In 
addition, it was found that EGFR levels in normal breast tissue were similar to the 
levels found in EGFR-positive breast cancers -except for the three tumors in which 
EGFR levels up to 3600 fmol/mg of membrane protein were found- indicating that 
in the majority of breast tumors EGFR is not overexpressed. Moreover, since the 
dissociation constants of the EGFR found in normal and carcinomatous breast 
tissue were comparable it is most likely that the EGFR present in both tissues is 
similar. 
EGFR ligand(s), present in all breast tumors, were also detectable in virtually all 
(94%) normal breast tissues. In contrast with EGFR it was found that breast tumors 
contained significantly higher levels of EGFR ligand(s) than did normal breast 
tissues. 
The finding that EGFR ligand(s) and the EGFR are ubiquitously present in normal 
breast tissue suggests that apart from a role in breast tissue carcinogenesis, the 
EGF-EGFR pathway is implicated in normal breast tissue growth and development. 
In conflict with the fact that normal breast tissue has been shown to be one of the 
steroid hormone target tissues and the dogma that there is no steroid hormone 
action without the presence of its receptor, normally no ER (nor PgR) can be 
demonstrated in these tissues by means of ligand binding assay. Lack of normal 
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breast tissue cellularity has been proposed as an explanation for this discrepancy 
since immunohistochemistry showed ER to be present in normal breast tissue 
epithelial cells. In contrast, EGFR, which was demonstrated to be specifically 
expressed at breast epithelial cell membranes also by immunohistochemistry, was 
readily detectable in the normal breast tissues. Therefore it seems likely that in 
normal breast tissue ER, although present, is expressed at levels, too low to be 
picked up by ligand binding assay. 
From the studies presented in this thesis it is clear that: the axillary lymph node 
status still is the most powerful prognostic factor in human breast cancer. The 
EGFR, although significantly associated with prognosis, offers no additional 
prognostic information if ER and/or PgR data are already available. In contrast, 
EGFR ligand(s), the nature of whom still remains to be established, seem to offer 
independent prognostic information. The data on EGFR and EGFR ligand (s) need 
to be expanded and longer follow-up as well as treatment data have to be awaited 
to fully evaluate the prognostic significance of these factors. 
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Nederlandstalige samenvatting 
De teleurstellende resultaten van uitgebreide lokale chirurgische behandeling van 
borstkanker hebben geleid tot de opvatting dat borstkanker meestal reeds een 
systeemaandoening is op het moment van eerste klinische detectie. Deze opvatting 
leidde medio jaren tachtig tot de introductie van adjuvante systeemtherapie. 
Inmiddels is uit 'meta'-analyses duidelijk gebleken dat subgroepen van patiënten 
met borstkanker baat hebben bij adjuvante therapie. Een meerderheid ondervindt 
echter alleen de nadelen. Deze onbevredigende situatie leidde tot een speurtocht 
naar factoren die de kans op metastasering van borsttumoren en/of de kans op 
een positieve reactie op een -adjuvante dan wel een palliatieve- systeemtherapie 
kunnen voorspellen (Hoofdstuk 1). 
Bekende en alom geaccepteerde prognostische factoren zijn onder andere: leeftijd 
van de patiënt, axillaire lympheklierstatus, grootte van de primaire tumor, histologie 
van de tumor, histologische differentiatie-graad en de steroidhormoonreceptor-
(Oestrogeen Receptor (ER) en Progesteron Receptor (PgR)) status van de primaire 
tumor. De steroidhormoonreceptor-status is naast een prognostische factor met 
name ook een criterium bij het maken van een keuze tussen een endocriene dan 
wel een chemotherapeutische -adjuvante en/of palliatieve- systeemtherapie. 
Ondanks de bewezen prognostische waarde van al deze factoren blijft het moeilijk 
om voor de individuele patiënt een gefundeerde schatting van zowel de prognose 
als van de reactie op een systeemtherapie te maken. Aanvullende prognostische 
factoren zijn daarom onontbeerlijk (Hoofdstuk 1). 
In 1987 werd voor de eerste maal aangetoond dat de Epidermale Groeifactor 
Receptor (EGFR) van prognostische betekenis was voor patiënten met 
borstkanker. Toen duidelijk werd dat de EGFR en de ER een onderlinge 
samenhang vertoonden is het besluit genomen om deze receptor en haar 
ligand(en) nader te bestuderen. 
In tegenstelling tot de in de celkern gelegen steroidhormoonreceptoren is de EGFR 
een celmembraan gebonden receptor, die autocrien of paracrien geproduceerde 
liganden bindt en waarvan het membraangehalte onderhevig kan zijn aan "down-
regulatie". Terwijl voor de ER (oestrogeen) en voor de PgR (progesteron) de 
liganden geïdentificeerd en gekarakteriseerd zijn, bestaat er voor de EGFR 
onduidelijkheid betreffende het in tumoren en in normaal borst weefsel aanwezige 
ligand. De volgende peptiden komen bij de huidige stand van kennis in 
aanmerking: Epidermale Groeifactor (EGF), Transforming Growth Factor α, 
Vaccinia Growth Factor, Amphireguline en Crypto. Alle zijn zij instaat om aan de 
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receptor te binden en deze te activeren (Hoofdstuk 1). 
Bij de aanvang van de in dit proefschrift beschreven studies bestond er geen 
algemeen geaccepteerde methode voor de bepaling van EGFR in humane 
weefsels. Zoals beschreven in hoofdstuk 2, ligt in het ontbreken van zo'n 
standaardmethode waarschijnlijk de grootste oorzaak van de enorme variatie in 
EGFR-waarden evenals in associaties tussen EGFR en patiënten-karakteristieken, 
tumor-karakteristieken, ziektevrije- (DFS) en uKeindelijke overleving (OS), zoals in 
de medische literatuur gerapporteerd. Tevens ontbraken en ontbreken nog steeds 
specifieke, goed gekarakteriseerde antilichamen voor een aantal van deze 
liganden. 
Allereerst is daarom een methode ontwikkeld voor de meting van EGFR. Deze 
"ligand binding-assay", die gebruik maakt van Hydroxylapatite (HAP) voor de 
scheiding van vrij en receptor gebonden EGFR tracer staat summier beschreven in 
hoofdstuk 3. Inmiddels is deze methode door de Europese Organisatie voor 
Onderzoek en Behandeling van Kanker (EORTC) overgenomen om als standaard 
te fungeren voor de meting van EGFR. Door gebruik te maken van een EGFR 
bevattend humaan placentapreparaat is deze methode tevens geschikt om het 
gehalte aan EGFR-liganden te meten in uit borsttumoren verkregen cytosolen 
(Hoofdstuk 3). Omdat het tot op heden niet duidelijk is welke van de vijf potentiële 
EGFR-liganden aanwezig is (of zijn) in borsttumoren noch in normaal borstweefsel, 
is deze laatste methode gebruikt om EGFR-liganden in de verschillende 
borstweefsels te meten. Een uitvoerige beschrijving van de HAP-methode vindt de 
geïnteresseerde lezer in het proefschrift van C.B.M. Kienhuis, getiteld: Measurement 
of the Epidermal Growth Factor Receptor, academisch proefschrift, Nijmegen, 
1992, dat gelijktijdig met het onderhavige proefschrift verschijnt. 
Om de waarde van EGFR voor de prognose van patiënten met borstkanker te 
kunnen schatten, werd in een prospectieve studie EGFR gemeten in 725 uit 
primaire borsttumoren geïsoleerde celmembraan-preparaten. Daar deze 
membraanpreparaten gedurende 1 maand tot 3 jaren voorafgaand aan de 
metingen opgeslagen zijn geweest, was het van essentieel belang om na te gaan 
of er gedurende opslag EGFR verloren was gegaan. Dit bleek niet het geval 
(Hoofdstuk 4). Er mocht dan ook geconcludeerd worden dat, gegeven de 
omstandigheden in het laboratorium (opslag van geïsoleerde celmembranen bij -
80oC in een bacitracine houdende buffer) EGFR stabiel was bij opslag gedurende 
minimaal drie jaren. 
Uit statistische analyse bleek een verband tussen het membraan-eiwitgehalte en 
het percentage EGFR-positieve tumoren. Dit verband was echter beperkt tot 
membraan-eiwitwaarden lager dan 0.2 mg/ml (Hoofdstuk 4). Het lage percentage 
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van EGFR-positieve tumoren gevonden bij deze lage membraan-eiwitgehaltes 
(<0.2 mg/ml) duidde erop dat beneden deze grens geen betrouwbare EGFR-
meting meer mogelijk is. De meest waarschijnlijke verklaring voor deze bevinding is 
dat beneden 0.2 mg/ml membraan-eiwit lage EGFR-waarden niet meer 
gedetecteerd kunnen worden met de HAP-assay en er daardoor fout-negatieve 
meetresultaten gegenereerd worden. Om die reden is de grenswaarde van 0.2 
mg/ml membraan-eiwit ingevoerd als minimum voor een betrouwbare EGFR-
meting. Hierdoor konden de resultaten van 194 EGFR-bepalingen niet worden 
opgenomen in het prospectieve klinische onderzoek (Hoofdstuk 4). 
Van de aldus resterende 531 membraanpreparaten bevatte 57% EGFR, een 
percentage dat beduidend hoger ligt dan het gemiddelde percentage van 40% 
(voor ligand-bindingsanalyse en voor immunohistochemische technieken) zoals 
berekend uit literatuur-gegevens (Hoofdstuk 2). Met uitzondering van drie 
membraanpreparaten, lagen de EGFR-waarden tussen de 3 en de 300 fmol/mg 
membraan-eiwit. In die drie membraanpreparaten werden waarden variërend van 
1500 tot 3600 fmol/mg membraaneiwit gevonden. De negatieve associatie tussen 
EGFR en ER, evenals tussen EGFR en PgR, in de literatuur reeds vermeld, werd in 
deze studie bevestigd. Het bleek dat 50% van de ER-positieve tumoren EGFR 
bevatte, terwijl dit percentage voor ER-negatieve tumoren 90% bedroeg. De 
verdeling van EGFR-positieve tumoren vertoont daarmee een sterke gelijkenis met 
die van patiënten met borstkanker die ten tijde van metastasering resistent bleken 
tegen endocriene behandelwijzen (Hoofdstuk 4). Deze laatste bevinding deed de 
hoop rijzen dat meting van EGFR wellicht aanvullende prognostische betekenis zou 
kunnen hebben. 
Een prospectieve klinische studie toonde aan dat er, naast een negatieve 
associatie tussen EGFR en ER (PgR), ook een negatieve associatie bestond tussen 
EGFR en de leeftijd van de patiënt. Tevens werd er een tendens tot lagere EGFR-
waarden bij postmenopausale vrouwen gevonden en werd een aanwijzing 
verkregen dat met het voortschrijden van de dedifferentiatie het percentage EGFR-
positieve tumoren toenam. "Multivariate'-analyse toonde echter aan dat al deze 
associaties verklaard dienden te worden uit associaties van deze factoren met ER 
(Hoofdstuk 5). 
De analyse van de associatie tussen EGFR en DFS respectievelijk OS, bracht aan 
het licht dat, indien 50 fmol/mg membraan eiwit werd ingevoerd als een 
grenswaarde voor EGFR-positrviteit, hoge EGFR-waarden significant geassocieerd 
waren met een kortere DFS evenals een kortere OS (Hoofdstuk 5). Ook de leeftijd 
van de patiënt, de axilläre lympheklierstatus, de tumorgrootte, de 
tumordifferentiatiegraad, ER en PgR bleken significant geassocieerd met DFS en/of 
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OS. Niettemin bleek wederom via multivariate-analyse dat, naast de axilläre 
lympheklierstatus, van de receptoren alleen de PgR onafhankelijke prognostische 
informatie verschaft en de EGFR niet (Hoofdstuk 5). 
Onderzoek naar de aanwezigheid van EGFR-liganden in tumorcytosolen 
(Hoofdstuk 6) liet zien dat alle 121 geanalyseerde tumoren deze liganden bevatten. 
Het bleek dat er een negatieve associatie bestond tussen de gehaltes van EGFR 
ligand en EGFR. Deze bevinding kan worden geduid als een uiting van receptor-
"downregulatie" door zijn ligand. Deze bevinding lijkt strijdig met de veronderstelling 
dat patiënten met een EGFR-positief mammacarcinoom een slechtere prognose 
hebben als gevolg van sterkere stimulering van de tumorgroei door endogeen 
geproduceerd ligand. Bij de bespreking van de resultaten van de prognostische 
betekenis van EGFR-positiviteit werd benadrukt dat de associatie tussen EGFR en 
groeisnelheid (gemeten aan de duur van het ziektevrije interval en de overleving) 
geen onafhankelijke is, maar geheel verklaard kan worden door de (negatieve) 
associatie tussen EGFR en steroidhormoon-receptor gehaltes. In tegenstelling tot 
de negatieve associatie tussen EGFR-liganden en EGFR, bleek er een positieve 
associatie te bestaan tussen het tumorgehalte aan EGFR-ligand en dat van de 
steroidhormoon-receptoren. 
In dit deel van het onderzoek bleek tevens dat hoge EGFR-llgand-waarden 
geassocieerd waren met een kortere DFS (Hoofdstuk 6). Onderverdeling naar de 
EGFR-status van de tumor leerde dat dit verschil in DFS het meest uitgesproken 
was in EGFR-positieve tumoren. Voor het feit dat hoge EGFR- evenals hoge EGFR-
ligand-waarden, twee factoren die negatief met elkaar zijn geassocieerd, ieder op 
zich geassocieerd zijn met een kortere DFS is op dit moment geen passende 
verklaring voorhanden. 
De voorlopige gegevens over de prognostische betekenis van EGFR-ligand(en) 
(van welke aard dan ook) lijken er op te duiden, dat de groeisnelheid van een 
tumor bevorderd wordt, wanneer meer endogeen EGFR-ligand voorhanden is. 
Omdat EGFR-ligand door binding aan EGFR tot internalisatie van de receptor leidt, 
vernacht men een negatieve associatie tussen het cytosol-gehalte aan EGFR-
ligand en membraan gebonden receptorgehalte. Zulks werd ook gevonden. 
Blijft dan het vraagstuk van de statistisch weliswaar zwakke, maar toch positieve, 
associatie tussen de tumor-gehaltes van EGFR-ligand en steroidhormoon-
receptoren. Terwijl de eerste factor de prognose van patiënten met een 
mammacarcinoom zou verslechteren heeft de tweede juist een gunstige invloed. 
Uit in vitro onderzoek van borsttumorcellen is bekend dat oestradiol de productie 
van EGFR-ligand bevordert. In zoverre hoeft de positieve associatie niet te 
verwonderen. Wat betreft de tegengestelde prognostische betekenis van EGFR-
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ligand en steroidhormoon-receptor wordt er op gewezen dat de eerste een 
onafhankelijke prognostische factor is en de tweede niet (Hoofdstuk 6). Indien bij 
analyse van grotere aantallen tumoren deze laatste gevolgtrekking overeind blijft, 
zou de conclusie wellicht moeten luiden, dat de associatie tussen de aan- of 
afwezigheid van steroidhormoon-receptoren en een betere of slechtere prognose 
voor de patiënt alleen geldt indien de daarbij voorhanden hoeveelheid 
groeifactor (en), relatief laag, respectievelijk hoog is. Onze nog beperkte 
waarnemingen laten het nog niet toe een dergelijke conclusie nu al te trekken. 
Gegevens betreffende de associaties tussen de aanwezigheid van een actief EGF-
EGFR systeem en de reactie van een patiënt op een systemische (adjuvante en/of 
palliatieve, endocriene en/of chemo-) therapie zijn op dit moment nog niet 
voorhanden. Recent onderzoek in een in vivo muizeborsttumor-model naar de 
associaties tussen ER, PgR, EGFR, EGFR-liganden en hormoon-afhankelijkheid van 
de betreffende tumoren wijst in de richting van een associatie tussen hoge EGFR-
waarden en hormoon-onafhankelijkheid (C.B.M. Kienhuis: 'Measurement of the 
Epidermal Growth Factor Receptor', academisch proefschrift, Nijmegen, 1992). In 
dit model werd ook een negatieve associatie tussen EGFR en EGFR-liganden 
gevonden, evenals een positieve associatie tussen EGFR-liganden en ER, 
respectievelijk PgR. Dit model lijkt dan ook geschikt om de relaties tussen EGFR, 
EGFR-liganden en borsttumor-groei, evenals die tussen EGFR, EGFR-liganden en 
de steroidhormoon-receptoren nader te bestuderen. 
Naast de 725 borsttumoren werden ook 36 normale borstweefsels, verkregen uit 
mammareductie-preparaten, geanalyseerd op hun EGFR-gehalte (Hoofdstuk 7). 
Hierbij bleek dat 32 (90%) van de 36 normale borstweefsels EGFR bevatten. 
Tevens bleek tot veler verrassing, dat met uitzondering van drie tumoren met 
uitzonderlijk hoge waarden de EGFR-gehaltes in de normale borstweefsels gelijk 
zijn aan die in EGFR-positieve borsttumoren. De overeenkomst tussen de 
dissociatie-constanten, gevonden in normaal borstweefsel en in tumoren, doet 
vermoeden dat in beide weefsels een zelfde EGFR aanwezig is. Hiermee kwam de 
algemeen geldende theorie dat de slechtere prognose van patiënten met EGFR-
positieve tumoren enigerlei relatie heeft met verhoogde receptor-niveaus op de 
helling. Daarentegen lijkt het zelfs veel waarschijnlijker dat een verlies aan EGFR 
tijdens de groei van borsttumoren optreedt. 
In normaal borstweefsel bleken ook EGFR-liganden meetbaar aanwezig in vrijwel 
alle (90%) gevallen. In borsttumoren werden echter significant hogere waarden van 
EGFR-liganden gevonden dan in de normale borstweefsels (Hoofdstuk 7). Mogelijk 
veroorzaakt deze toename van EGFR-liganden in borsttumoren een downregulatie 
van membraan-gebonden EGFR en ligt in dit laatste feit, zoals reeds is 
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gesuggereerd, de verklaring voor het verlies aan EGFR in borsttumoren. 
De bevinding dat EGFR en EGFR-liganden beide aanwezig zijn in vrijwel alle 
normale borstweefsels lijkt er op te duiden dat dit receptor-mechanisme betrokken 
is bij het normale groeiproces van dit weefsel. Het feit dat er meestal geen ER 
(noch PgR) in de normale borstweefsels wordt aangetroffen, indien geanalyseerd 
met behulp van een ligand binding-assay, lijkt in strijd met het adagium dat er 
zonder hormoon-receptor geen hormonale invloed op een weefsel kan bestaan. 
Met behulp van immunohistochemische technieken is echter wel ER (PgR) in 
normaal borstweefsel aangetoond. Een populaire verklaring voor deze discrepantie 
is gezocht in de, vergeleken met borsttumoren, geringe celrijkdom van het normale 
borstweefsel. Het feit dat EGFR -een receptor die zoals werd aangetoond door 
middel van immunohistochemische technieken ook specifiek geëxprimeerd is op 
borst-epitheelcellen- goed aantoonbaar is in deze weefsels is hiermee in 
tegenspraak. Het ziet er dan ook naar uit dat de verklaring voor de discrepantie 
tussen hormoongevoeligheid van normaal borstweefsel en de afwezigheid van ER 
eerder moet worden gezocht in het feit dat de expressie van ER in normaal 
borstweefsel relatief laag is. 
Uit resultaten van de studies beschreven in dit proefschrift valt af te leiden dat de 
axillaire lympheklierstatus nog steeds de beste prognostische factor is voor 
patiënten met een mammacarcinoom. EGFR is wel significant maar niet 
onafhankelijk geassocieerd met de prognose van patiënten met een 
mammacarcinoom. EGFR-gegevens verschaffen geen additionele prognostische 
informatie wanneer de waarden van ER en/of PgR bekend zijn. In tegenstelling tot 
EGFR, zijn EGFR-liganden, waarvan de karakterisering recent ter hand is genomen, 
waarschijnlijk wel onafhankelijk geassocieerd met prognose. Lange termijn-
gegevens dienen te worden afgewacht om de prognostische betekenis van het 
EGF-EGFR systeem in de kliniek van het mammacarcinoom op zijn waarde te 
schatten. 
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